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ABSTRACT
Emily Lynn Butler: Using Patient Preferences to Estimate Optimal Treatment
Strategies for Competing Outcomes
(Under the direction of Michael R. Kosorok)
Treatment decisions should be tailored as close as possible to heterogeneous dis-
ease populations because diversity permeates through all levels of patient information.
This can include genetic makeup, demographic variables, or individual goals as to what
qualifies as a successful outcome; hence, patient treatment plans should account for all
of these factors. This area of clinical research, coined precision medicine, focuses on
combining a multitude of considerations to make treatment decisions as personalized
as possible. In this sphere, the statistical contribution involves methodology that most
accurately maps patient information to the set of treatment options. While there has
been a plethora of research developing personalized treatment plans, they are central-
ized around creating optimal strategies for only one outcome. There has been limited
work done to estimate personalized treatment plans for patients interested in balancing
competing outcomes. This work seeks to fill that gap. One way of balancing competing
outcomes is to incorporate the patient’s preferences regarding these outcomes in the
development of a utility function to be used in the estimation procedure. Since it is not
possible to directly observe a patient’s preference in standardized numerical form, we
solve this using a preference elicitation questionnaire in conjunction with item response
theory. We derive a posterior estimate of each patient’s latent preference information
and use it to define a utility function that represents the patient’s inherent trade-offs
between the outcomes. The optimal treatment choice is that which provides the largest
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expected utility for each patient, conditional on the patient’s prognostic information.
This estimation technique is extended to the multi-stage treatment scenario which re-
quires sequential decision making. Estimating the latent preference value now involves
the patient’s contentment with results from previous stages along with the evolution of
the patient’s preferences. Once the composite outcome is defined, Q-learning is used
to determine which treatment elicits the largest expected utility given the patient’s
prognostic information, while assuming that the optimal treatment will be chosen in
the future. Finally, to make the estimation technique more flexible, we propose a non-
parametric approach to both estimating the latent preference and defining the utility
function via monotone splines.
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CHAPTER 1: INTRODUCTION
Advancements in many areas have contributed to the vast incorporation of pre-
cision medicine in current patient treatment plans. This includes, but is not limited
to, genetically determining which biomarkers are associated with particular diseases
(Jain 2002), increased efficiency of drug delivery systems (Allen and Cullis 2004), and
more complex data collection procedures which provide richer data to make inference
on (Cai et al. 2011). The goal of precision medicine is to incorporate a parsimonious
amount personalized information to efficiently determine which treatments are best
for which types of patients (Norvig et al. 2010, Hamburg and Collins 2010). This re-
sults in strategies that treat particular diseases by targeting a certain genetic marker,
strategically controlling the amount and frequency of dosages and determining which
patients should be receiving which treatments based on their demographic and clinical
information.
A key component of precision medicine is creating mathematical estimators for
clinical decision making. Statistical methodological research provides a objective way
to predict which treatment, or which sequence of treatments, will lead to the best
outcomes for each patient. While this type of work covers a wide variety of solutions to
real world problems, there are always existing methods that can be improved upon or
new areas to be explored. Many of the current optimal treatment estimation strategies
are only designed with one outcome in mind. However, for a lot of patients, and
a lot of therapeutic areas, it is more likely that many outcomes affect a patient’s
overall wellness. A patient may need to balance two failing organ systems, efficacy
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and side effect burden, or even quality of life and cost. There are currently three
primary approaches to estimation of optimal individualized decision rules for competing
outcomes: (i) set-valued treatment regimes (Laber et al. 2014b, Lizotte and Laber
2016); (ii) inverse-preference elicitation (Lizotte et al. 2012a) ; and (iii) constrained
estimation (Linn et al. 2016). Each of these either assumes a fixed composite outcome
or does not address patient preferences directly through elicitation.
While the ideal situation is to directly elicit patient preferences, the type of elic-
itation where the patient chooses parameters to define a composite outcome is not
feasible unless patients have undergone specialized training (Brennan 1998, Braziunas
2006, Lizotte et al. 2012a). Thus, the preferences must be indirectly estimated from
information that can be directly obtained. A common approach for preference elicita-
tion is to administer an itemized questionnaire that characterizes how the patient feels
about each outcome in relation to the other. We assume the questionnaire is comprised
of a series of binary responses to each question and use item response theory (Embret-
son and Reise 2013) to estimate the conditional distribution over these preferences. We
use this conditional distribution to derive preference-sensitive optimal individualized
treatment strategies for each patient.
This work proposes three methodological advancements that seek to solve the
problems presented here. For these purposes, we only assume two competing out-
comes. This research aims to develop rigorous, yet practical, ways to elicit and estimate
a patient’s latent preference information and incorporate it when making treatment de-
cisions. This ensures that patients play a key role is decision making and offers a clear,
logical way to link patient’s preference and outcomes to create a well-defined utility
function that serves as a composite outcome. The first method presented predicts
single stage individualized treatment rules by estimating the latent preference infor-
mation conditional on the itemized responses through the Rasch model (Rasch 1961;
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1980). This preference information is standardized and incorporated into a linear util-
ity function. The optimal treatment rule is that which optimizes the expected utility
function for a given set of patient covariates. The second method extends this to the
multiple stage scenario where the preference information is updated at each treatment
stage based on how a patient’s preferences have changed and their overall contentment
with their health status. Using a reinforcement learning technique called Q-learning
(Watkins and Dayan 1992), the optimal treatment rule is determined as that which
provides the maximum expected utility given the patient’s history, assuming that the
best treatment is assigned at all subsequent stages. The final method provides a more
flexible estimator by solving this problem nonparametrically. The preference informa-
tion is conditioned on the itemized responses through constrained monotonic splines
(Villalobos and Wahba 1987). To estimate the patient’s ideal trade off between the
two outcomes, we define a nonparametric utility function using monotonic splines once
again to calibrate the patient’s satisfaction with the outcomes after receiving the treat-
ment. This more accurately captures the patient’s feelings on how to weigh the two
outcomes.
Obtaining data to evaluate this methodological research is difficult because the
specific measures required are not collected during standard clinical trials. We are
fortunate enough to obtain data from the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) schizophrenia trial (Stroup et al. 2003), which can be used in
the single stage, linear model. Unfortunately, when this line of work was extended to
two stages or incorporates a nonparametric estimator, the model assumes information
that was not collected in this trial nor was found in any other trial of its kind. How-
ever, the set of up the CATIE trial can serve as a motivating example for the single
stage, multistage or nonparametric paradigms. Schizophrenia is a chronic, severe and
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debilitating mental disorder that may make patients lose touch with reality and can af-
fects mental cognition, emotional stability and social behaviors (Andreasen and Flaum
1991). Since it cannot be cured at this time, treatments are designed solely to alle-
viate symptoms. One of the main treatments for schizophrenia is the administration
of antipsychotic medications. Some of these antipsychotics elicit negative side effects
in the patient, making it difficult for them to adhere to the treatment regimes, while
others are less efficacious but also have less side effects (Lieberman et al. 2005). It is
important to develop treatment plans that can find the appropriate balance between
relieving schizophrenic symptoms and reducing the side effect burden. We can use this
example to provide a realistic scenario when generating data for our simulation study.
While this is one example of the application for this work, similar comparisons can be
made with diseases such as rheumatoid arthritis and diabetes.
The remainder of this thesis is divided into the following chapters: chapter 2
contains a literature review that includes an introduction to item response theory and
methods for single and multiple stage estimation; chapter 3 contains a method for in-
corporating patient preference when estimating a linear utility function in the single
stage paradigm; chapter 4 extends this method to a multi-stage decision making process
that incorporates evolving patient preferences and the patient’s contentment with the
results; chapter 5 provides a nonparametric approach to incorporating patient prefer-
ences for single stage estimation; and chapter 6 briefly summarizes the work presented
and provides thoughtful areas of extension.
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CHAPTER 2: LITERATURE REVIEW
2.1 Introduction
Personalized medicine is the practice of tailoring healthcare plans to patients as
individualized as possible. In an ideal setting caregivers are able to account for patient
history, genetic information, response to treatment, and other relevant factors when
assigning each treatment throughout the entire course of the disease. These treat-
ments would be assigned based on how each patient is progressing at each stage and
which sequence of treatments is best earns the optimal expected long term response.
These treatment plans have been coined dynamic treatment regimes (DTRs) and es-
timating DTRs is the main goal of personalized medicine. These treatment plans are
unique in the sense that they are not predetermined at the initial doctor’s visit as a
blanket treatment for all patients. Instead, only the first treatment is decided at the
initial visit (either a generic starting treatment or one determined by the patients/
baseline characteristics) and subsequent treatments are determined at each follow up
period based on their progress. This makes the treatment regime dynamic through
time. The evidence based treatment decisions are determined by the patients’ response
to the course of treatment and uses prognostic and treatment information to define
their history (Collins et al. 2007). DTRs have four components: decision points (time
points at which the decisions are made), tailoring variables (patients’ prognostic in-
formation used to make treatment decisions), intervention components (the type or
dose/intensity/duration of the treatment), and decision rules (a function that links the
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tailoring variables to the intervention options at decision points) (Collins et al. 2014).
In the statistical framework, DTRs are developed to create mathematically de-
pendent treatment plans that mimic how clinicians treat patients in practical settings.
This quantitative way of estimating treatment plans is a new and novel way to think of
treating patients. Preliminary interest in this way of thinking began in the mid-1980s
when researchers were evaluating two stage dynamic treatment strategies for cancer pa-
tients. In the 1990s the idea of a two stage customized treatment plan expanded when
psychiatrists were interested in expanding to k-stage treatment plans. By the early
2000s, clinical trials and treatment strategies were implemented by doctors studying
DTRs in substance abuse and mental health research (Lavori and Dawson 2014). Once
the physician or researcher has conjured a list of potential DTRs, they need to be
evaluated in a special clinical trial called a Sequential Multiple Assignment Random-
ization Trials (SMART) (Murphy 2005a). The development of SMARTs began when
traditional clinical trial designers were looking to identify an intermediate outcome be-
tween randomization and the primary outcome and make an appropriate reaction to
this outcome. The goal was to be able to assess the status of the patient throughout
the trial and adjust the treatment as necessary.
It is important to highlight the distinction between DTRs and SMARTs. A DTR
is a treatment strategy that tells the caregiver which (sequential) treatment plan will
lead to the highest probability of success and adapts to the patient’s health status
throughout the course of treatment. A SMART design is an experimental trial with
the purpose of determining which DTRs are optimal for which patients. A SMART is
able to evaluate the various DTRs because it compares between them by randomizing
patients to preselected treatments. A SMART can have two goals: compare a small
number of prespecified DTRs embedded in the SMART design or construct new DTRs
which may not be naturally embedded in the design.
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The material presented in this literature review is meant to be a survey of current
statistical methods used to estimate dynamic treatment regimes in the context of using
data collected in a SMART trial. Chakraborty and Moodie (2013) have published a
book titled “Statistical Methods for Dynamic Treatment Regimes” which covers this
and similar topics in some depth. In this book, the authors discuss select topics such
as SMART designs, observational studies, reinforcement learning and various methods
of estimating DTRs. Please refer to this book for an indepth description of a number
of useful methods for DTRs.
This review covers a brief introduction to item response theory, how to design
a SMART and what statistical methodologies exist to make inference from this data,
with particular emphasis on recent developments in the area. Section 2.2 introduces
item response theory and the Rasch model. Section 2.3 will highlight how a SMART
design fits into the overall development of a treatment strategy, the importance of pilot
studies, practical considerations such as sample size, calculations, and handling missing
data, as well as the future of data collection. Section 2.4 describes select methods for
choosing tailoring variables. Section 2.5 introduces methodological results for the single
stage paradigm and section 2.6 provides methodological results for the multiple stage
paradigm. Section 2.7 describes methods designed to develop DTRs when the only data
available is observational because a randomized design is not practical, is impossible,
or is unavailable. Section 2.8 describes the work done developing DTRs for competing
outcomes.
2.2 Item Response Theory
An important piece to this research is incorporating patient’s preferences into
their treatment decisions. To do this, a latent trait model from item response theory
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will be employed to estimate a subject’s implicit utility function regarding the two
competing outcomes so that it can be included in estimation. This is done by estimating
parameters from the Rasch model that is conditional on a unidimenional latent trait.
Item response theory (IRT) concerns the accuracy and development of test scoring
when these tests or questionnaires are designed to measure abilities, traits, or behaviors
(An and Yung 2014). The test or questionnaire consists of a set of items (questions) with
binary or ordinal responses. These models not only provide accuracy of test scoring,
but can also improve efficiency of data collection by only including the significant items.
Historically, IRT has been primarily used for psychological assessments and educational
testing, but these models have recently been extended to health research. This is
partially because of the aforementioned ability to tease out only the discriminative
items for inclusion. Outside of the education and psychological areas, IRT is referred
to as Latent Trait Modeling (LTM).
Formally, LTM is latent structure analysis of categorical data and can be thought
of as factor analysis for dichotomous or ordinal data (Uebersax 2000). To first under-
stand this idea, it is easiest to consider the model in terms of its latent structure. This
modeling technique reduces the set of dichotomous variables to a set of small factors
called latent traits. Their desirability stems from the fact they are formalized probabil-
ity models which relates the unobserved (latent) variables to the observed variables that
are measurable in real life. These latent trait models allow precise measurement of the
difficulty of items, determines the association of each item with a person’s proficiency,
determines which items are biased for different subpopulations, creates questionnaires
with the minimum number of items, measures accuracy at different levels of proficiency,
and allows for the ability to create adaptive tests where preceding items determine the
subsequent ones. From here on out, although interchangeable we will refer to both
LTM and IRT as just IRT. Within each line of thinking there are minor differences,
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but computationally they are essentially the same.
IRT is advantageous over classical test theory (CTT), one of the original methods
of test response analysis, because IRT takes both information from the person and the
items into account (Yu 2013). CTT cannot differentiate between the subjects profi-
ciency and the difficulty of the item; meaning for populations of different proficiencies,
the questionnaires could seem easy or difficult (An and Yung 2014). On the other hand,
IRT assesses both the difficulty of the question and the subject’s proficiency through-
out the entire questionnaire. Once the items are calibrated for the population, scores
for subjects can be compared even if they did not answer the same set of questions.
This calibration requires an iterative process because the proficiency and difficulty de-
termined by the data are used to fit the model which in turn predicts the data. The
ability to compare subjects who respond to different sets of items also reduces the size of
the questionnaire. This increases efficiency and in turn reliability because the precision
differs based on latent structure and can be generalized to the entire population. IRT
modeling is considered a superior analysis method and is employed in many standard-
ized exams, such as the Scholastic Assessment Test (SAT) and the Graduate Record
Examination (GRE) (An and Yung 2014).
One of the most well known models used in IRT is the Rasch Model (RM) (Rasch
1980). Before continuing, it is important to point out the philosophical differences be-
tween IRT modeling and Rasch modeling even though computationally they are similar.
Item response theory purists build models with the intention of creating a model that
fits reality, which contains a lot of parameters and becomes very complicated. Here,
the goal is to fit the model to the data. Rasch modelers seek to build elegant, sim-
ple models with more practical implications and fit the data to the model (Yu 2013).
The Rasch model is a model employed by item response theorists to analyze itemized
response data.
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The one parameter Rasch model is designed for dichotomized response data, i.e{1,0} where 1 corresponds to “yes" and 0 corresponds to “no". The probability of
responding “yes" is:
P (xij = 1∣θi, βj) = eθi−βj
1 + eθi−βj
where P (xij = 1∣θi, βj) is the probability of person i responding “yes" (1) to question j
(Li and Baron 2012). The latent trait, θi, is thought of as person i′s proficiency and
βj represents the difficulty of item j. The probability of answering yes to each item
is dependent on the person’s proficiency and item’s difficulty such that if the person’s
proficiency matches the item’s difficulty, that person has a 50% chance of answering
yes.
The Rasch model can be extended to a two parameter model by introducing a dis-
crimination parameter, which measures the slope, to allow more flexibility in modeling
(An and Yung 2014). In this model, the probability of responding “yes" is:
P (xij = 1∣θi, βj) = eαjθi−βj
1 + eαjθi−βj
where the discrimination parameter, αj, measures if the item has the ability to dif-
ferentiate subjects. A high discrimination parameter (αj) implies that the probability
of answering "yes" increases more rapidly as the proficiency parameter (βj) increases.
This parameter tells how effectively the item discriminates between highly and lowly
proficient students (Yu 2013)
These two models are utilized for dichotomous responses, but multiple extensions
of these models have been developed for increased flexibility. These include, but are
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not limited to, three and four parameter models, Bayesian IRT models, models used to
analyze ordinal responses (graded response models), and models used to analyze items
that can be explained by more than one latent trait (multidimensional models).
Letting piij = P (xij = 1∣θi, βj), the Rasch model can easily be transformed into a
logistic regression model (or a probit model) such that:
logit(piij) = αjθi − βj
where θi is the latent variable and αj, βj are parameters that can be estimated from
the data.
2.3 Study Design
A general framework used to create a clinical treatment strategy is the Multiple
Optimization Strategy (MOST) (Collins et al. 2005). The MOST is an engineering in-
spired framework which consists of 3 phases. First is the screening or preparation phase
where the intervention components are identified for inclusion or rejection. Treatment
or delivery methods are also chosen at this time based on theoretical assumptions de-
termined by the physician. Previously garnered information is used to create a guide
for the selection of intervention components, which questions need to be answered and
what outcome is being optimized. Second is the refining or optimization phase, where
the selection components are tuned and optimized with the goal of arriving at a final
proposal of the treatment protocol. The optimization phase is information gathering
and decides which treatment combinations achieve the optimization criterion via a ran-
domized experimental design that proposes a sequential treatment intervention. Last
is a confirmation or evaluation phase, where the optimized sequential intervention is
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evaluated in a traditional randomized controlled trial (RCT) where they investigate
efficiency and practicality. At times the first two phases need to be repeated before the
final stage can be implemented. The MOST assumes that experimentation makes the
most efficient use of available resources with the goal of producing the largest improve-
ment and treats optimization as a process rather than an endpoint.
Traditionally, the screening/preparation and refining/optimization phases used
a factorial or fully crossed analysis of variance (ANOVA) design. Because SMART
designs are considered a special case of the factorial design where not all factors need
to be crossed, they have been found to be advantageous to replace the ANOVA model
in the second phase. A SMART creates the adaptive intervention by allowing for
dynamic treatments (as opposed to fixed ones) and provides a basis to identify the
best tailoring variables and decision rules. Recall that tailoring variables are essentially
patients’ prognostic information used to make treatment decisions and the decision rule
is a way of choosing which treatment to assign. They investigate the best sequencing
of intervention components, what tailoring variables should be used, when and how
frequently should these tailoring variables be assessed, and should one treatment be
assigned or should patients have the ability to choose from a list of options. The
treatments are assessed as an entire treatment sequence and not isolated by phase of
treatment. They involve multiple randomizations over time, where each randomization
point corresponds to a decision point and questions are investigated regarding two
or more treatment options at each decision point. Additionally, responders and non-
responders are controlled for by design because different treatment decisions need to
be considered for each (Collins et al. 2007; 2014).
Consider a generic example for illustration. A 2 stage SMART enrolls 200 par-
ticipants with equal randomization such that it assigns 100 patients to treatment A
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and 100 patients to treatment B at stage 1. At the end of stage 1 the patients’ re-
sponse to the treatment is assessed using the response variable or tailoring variables,
and the patients are classified as either responsive or nonresponsive. What defines re-
sponsive or nonresponsive should be determined a priori. Each of the patients is then
re-randomized according to their response classification. For instance, patients who
responded to treatment A are assigned to stay on treatment A at stage 2, while the
patients who did not respond to treatment A are randomized to treatment C or D.
A similar situation could arise for treatment B where responders stay on treatment B
and nonresponders are randomized to treatments E or F. In this scenario, there are 6
DTRs: A-A A-C A-D B,B B,E B,F. Alternatively, responsive patients could also be
re-randomized. There could be more than 2 randomization options at each stage, or
the nonresponsive patients could switch from A to B or vice versa. The randomization
also does not need to be balanced, and the stages could be extended beyond only 2. In
this example data would be collected at 3 time points: baseline, time 1 (after the first
stage of the study but before the patient is re-randomized to the second treatment),
and time 2 (after the second stage or at the end of the study). Generally speaking,
randomization does not need to depend on responder status, although this is the case
in this example.
There are numerous reasons it is advantageous to use a SMART. For example,
it has the desirable quality of making better use of the pre-determined sample size
and can answer more clinical questions than a RCT. In a two phase trial, the first
phase of the trial can be assessed by comparing the mean outcomes between the first
two lines of treatment. The second phase can compare the effect of the treatment
options for responders and nonresponders, regardless of their first line of treatment.
This increases the power of the hypothesis tests, since they recycle the patients in
the second phase of the study. Most importantly, the design then has the ability
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to compare the embedded treatment regimes that pool information across multiple
experimental conditions by, again, recycling patients through the trial (Collins et al.
2014). While the main goal of a SMART is to mine data used to develop DTRs, they
have other uses, such as discovering which treatments work best sequentially to obtain
an improved outcome, investigating the interplay between trajectories of the patients
disease progression and treatment sequences, comparing different treatment sequences,
and investigating the benefit of both prognostic information and observable data in
determining individualized treatments (Almirall et al. 2012).
Now that it is clear what a SMART is, why it is beneficial, and what research
would benefit from it, what does one do next? How does one begin to design a SMART?
The answer, as in most clinical trials, lies with running a pilot study. When research-
ing any new treatment or treatment strategy, a pilot study is always advised, if not
required, and this is no different. A good pilot study is great practice for implementing
a larger design, gives critical value estimates, is important for sample size estimation,
and provides a preliminary look at the utility of the proposed treatments. The novelty
of SMARTs raises feasibility concerns which makes a pilot study even more crucial for
designing an effective and efficient SMART. Note that a SMART pilot is usually per-
formed before the first phase of the MOST because it provides information required for
justification of a theoretical model. Almirall et al. (2012) highlights important topics
that researchers must be aware of when designing a SMART and how solutions can
be elicited through a pilot study: (1) considering the choice of a primary tailoring
variable. This will be used to determine the set of randomized treatment options such
as assessing response/non-response, when this decision should be made, what criterion
is used to make the decisions, frequency of assessment, how sensitive this measure is,
justification of its use, and feasible application in clinical treatment; (2) deciding which
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additional potential tailoring variables should be collected, such as either baseline pa-
tient characteristics or time varying measures. These are determined as important in
predicting outcomes to later stage treatments; (3) deciding how to control for missing
tailoring variables. This should be guided by how it would be handled in clinical prac-
tice; (4) deciding between up-front randomization (randomization at the beginning of
the trial) or real-time randomization (randomized sequentially at each decision point
which allows for clinical information to be used in randomization); (5) highlighting the
difference between research assessments for data analysis to develop adaptive treat-
ment strategies and assessments of the adaptive treatment strategies used to inform
the sequential treatment assessment; (6) identifying concerns clinicians have regarding
sequences of treatments offered and assessment of what determines response versus
nonresponse; (7) assessing for patient acceptability; (8) testing the language of consent
forms; (9) illuminating unanticipated tailoring variables that would be useful in the
subsequent SMART.
The pilot study provides crucial information to increase the probability of success
of a SMART. However, even with a pilot study, often times there is still not enough
information collected to prevent unanticipated hiccups. As previously stated, one goal
of a SMART is to identify embedded DTRs not embedded in the original design. A
great example of this is the analysis of SMART data collected from a study for the
treatment of advanced prostate cancer. Wang et al. (2012) created a new method to
compare dynamic treatment regimes and along the way, changed the definition of the
DTRs after the trial ended. This analysis is different than previous analyses using
the same data because they changed the definition of viable DTRs based on what had
been predetermined as a ‘missing observation’. The protocol required that patients
were re-randomized to a new treatment and if they did not complete it, they were
classified as missing. However, the treatment plan determined by the protocol was not
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feasible for patients with toxicity or disease progression. They altered one of the DTRs
to include those patients who had to leave the study because of toxicity where the
second treatment was the recovery treatment they were given after leaving the trial.
The viable DTRs were now defined by efficacy, toxicity and disease progression. The
authors also redefined this endpoint because it needed to quantify the health experience
of the patient over a pre-specified fixed period, not just their final tumor size or toxicity.
By now it should be clear that designing, implementing and analyzing SMARTs
is a relatively new area, which means there is still a lot of work to be done. While there
is a lot of methodological work needed or expanded upon (see subsequent sections),
there are still a lot of gaps in knowledge for designing these trials. One clear gap in the
literature is work on a universal (or adaptable) sample size formula. There are sample
size calculation publications for SMART designs, but there is no universally accepted
calculation for general use.
Fortunately, there has been some progress made in sample size formulas for
SMART design, such as the development of upper bound sample size estimates for
censored data. Unfortunately, this sample size formula does not have great general-
izability properties because the upper bounds are based on a Kaplan-Meier estimate
and the log-rank statistic. Li and Murphy (2011) developed a sample size formula for
a two stage randomized trial (with the goal of developing DTRs) for failure time out-
comes. The difficulty in such a calculation stems from the variances of the common
test statistics. These test statistics depend on the joint distribution of the time, early
response determination, and the primary failure time, which are likely to be depen-
dent. The sample size is derived using upper bounds on the variances in place of the
usual variances and, hence, the resulting formula only requires the same assumptions
of a traditional single stage randomized clinical trial. Using the upper bounds of the
variances, the proposed samples size formulas for the Kaplan-Meier estimate (nK) and
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the log rank statistic (nL) are
nK ≤ (Z1−α/2 +Z1−β)2σ2B{F¯1(τ) − F¯2(τ)}2
and
nL ≤ ( 1
pq
+ 1(1 − p)q) (Z1−α/2 +Z1−β)2ξ2 ´ t
0
F¯c(t)dF1(t)
respectively, where Z is the z-score for a standard normal distribution, α is the type I
error, β is the type II error, F¯ is the survival function, τ is the time at the end of the
study, p = p(A1 = 1) and q = p(A2 = 1∣R = 1) are the randomization probabilities, R is
the indicator of randomization, ξ is the log hazard ratio. Note that
σ2B = F¯ 21 (τ)pq
ˆ τ
0
dΛ1(t)
F¯1(t)F¯c(t) + F¯ 22 (τ)(1 − p)q
ˆ τ
0
dΛ2(t)
F¯2(t)F¯c(t)
where Λ is the cumulative hazard function. This sample size calculation has been
proven to provide the desired power if the hazards of the alternative are proportional.
This sample size calculation is most notable because the nature of chronic diseases (the
focus of SMARTs and DTRs) allows the outcome, or surrogate outcome, to be thought
of in terms of failure, even if death is not the primary endpoint. This means that this
sample size formula will be applicable in many settings, especially until further research
is done.
Another clear gap in the literature is lack of progress made in developing strate-
gies that prevent, and methodology that controls, for missing data. The construct of a
SMART requires numerous randomizations and multiple treatment prescriptions which
17
presents unique challenges when analyzing data in the presence of missing data. Impu-
tation strategies for handling missing data collected from SMARTs is an understudied
area at this time. Shortreed et al. (2014) presented the following five missing data
issues: (1) transition between treatment stages does not always occur at pre-specified
times but instead can be determined by a patient outcome; (2) some outcome variables
are irregularly spaced while some variables are collected at regularly scheduled study
visits; (3) observing some variables is dependent on a patient’s history, which results
in structural missingness for the data-dependent portion of the collected information.
(4) individuals are simply lost to follow up leaving the treatment stage; (5) some indi-
viduals are lost to follow up entering the treatment stage. Their proposed solution is a
flexible imputation strategy to facilitate valid inference using data from SMARTs which
is a time ordered, nested, conditional imputation strategy, which exploits the nearly
monotone pattern of missing data found in this type of longitudinal study. It ensures
that a complete multivariate prediction distribution exists while obtaining desirable
traits for inference across longitudinal outcomes. Assuming missingness at random,
this method works best when the data is imputed with a pseudo-Gibbs sampler, which
applies repeated iterations through the model. Multiple imputation is one of many
strategies used when working with missing data, and the type of strategy often de-
pends on the structure of the data and the nature of the missingness. This method
was not compared to other imputation strategies such as inverse probability weighting
or likelihood methods, and there is no contingency plan when the missingness is not
monotone. It is clear the presented work is exciting and promising progress, but more
headway is still needed.
While momentum in some necessary elements of SMART study design is stalled,
other areas are moving full speed ahead. An exciting area of expansion is data collection
and treatment allocation using mobile technology. The clear interest is the ability to
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increase access to fast accurate care because mobile technologies include but are not
limited to cell phones, sensors and monitors. The goal is development of evidence
based Just in Time Adaptive Interventions (JITAIs) that collects real time data from
patients and uses that data to inform the real time delivery of intervention options,
such as treatment, dose and timing of care (Nahum-Shani 2013). For example, trying
to intervene in heavy drinking and smoking, a mobile phone would be administered
and participants would be prompted 3 times a day to assess their smoking urge, affect,
and drinking behaviors. Urge management interventions would be delivered only if the
individual reports the urge to smoke at a specific time. Anytime during the day the
user can text either lapse or crave, and a series of encouraging text messages will be
sent back to their cell phone. Another example is managing eating disorders. When
treating college women with eating disorders, the subject would be provided with a
cell phone which receives 5 prompts regarding mood, eating behaviors, exposure, etc.
When she reports what is considered a negative mood she is recommended to use
one of the treatments provided via a CD. In all three instances, the interventions
are adapted and delivered through a mobile medium such that patient information
can be obtained at any time and responses can be administered at any time. The
variety of potential interventions includes reach out interventions, behavioral strategies,
cognitive strategies, and goal setting. Tailoring variables can be collected actively (self-
reported via prompting or user initiated) or passively (activity level, location, social
media activities, number of ignored recommended interventions, etc.). The decision
points vary depending on the goal of the treatment plan and can include a random
prompt, user requested help, or indication of specific experiences. The decision rules
can be deterministic (if the patient reports more than X then give them this, otherwise
give them that) or stochastic (determining the probability of an intervention). The
corresponding thresholds can be determined and optimized using reinforcement learning
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(which will be covered in later sections). Even though this concept is in the early
stages of development, there are obvious feasibility issues for this kind of treatment
implementation, such as cost and monitoring adherence. Innovative methods like this
have the ability to change the way patients are treated and can serve as a guide for
future treatment and collection methods.
A SMART is a novel approach to efficiently collect data which accurately esti-
mates DTRs for individualized patients. The basic design structure has been created,
trials are ongoing in the clinical setting, and new advances are being developed day by
day, but more work needs to be done. The flexibility of the design makes developing
broad techniques difficult, but the need and the talent is there to continue to make
advancements in what has become an extremely timely, interesting and applicable area
of study.
2.4 Variable Selection
Variable selection is an important component of estimating optimal DTRs because
tailoring variables are used to adapt the treatment plan to the individual. The goal is
to avoid a priori hand picking tailoring variables, but instead use the data to select a
subset of the tailoring variables that estimates a decision rule as close to the optimal
rule estimated when using all variables. Including all possible variables as tailoring
variables is inefficient and will often lead to over fitting. Once the tailoring variables
are selected, they can be used when optimizing DTRs. A brief overview of recent and
relevant variable selection techniques is included in this section.
Biernot and Moodie (2010) discuss two computer science techniques that can be
used for variable selection: the S-score criterion and the use of reducts. The S-score
of a variable shows the expected increase in response that is observed by choosing
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the treatment based on the value of that variable. It combines the interaction of the
covariate with the treatment and the proportion of the population exhibiting variability
in that covariate. Higher values indicate stronger relationships between the variable
and the treatment, and shows that a large proportion of patients would experience
change in the optimal action if the variable was taken into consideration. This scoring
is used to rank potential variables but each variable is evaluated separately meaning
correlation between variables is not taken into consideration. The S-score could also be
used sequentiality such that the variable with the highest score is first selected, then
the variable with the second highest score given the first variable is selected and so on.
The reducts approach was developed from rough set theory in computer science.
The positive region is a set of all observations that can be uniquely classified into one
equivalence class based on the non-decision variables. The reduct is the minimal set of
tailoring variables that classifies individuals into unique decision equivalence classes as
well as the complete set of variables does. Reducts help eliminate redundant variables
while preserving information regarding the similarity of individuals in the sample. In
the scenario with multiple reducts, one can select the variables most frequently seen in
the reducts, or can select amongst reducts by choosing the set of covariates with the
highest S-score. This last hybrid method is believed to combine the strengths of these
two methods. Unfortunately, it is important to note that reducts are not appropriate
for continuous outcomes.
Another way to approach variable selection is to simultaneously estimate optimal
treatment regimes and identify significant variables. This is done with a penalized
regression model that finds which variables interact with the treatment using a new
loss based framework. Lu et al. (2013) introduces a method which does not require
estimating the baseline mean function for the outcome of interest and is easily adaptable
to shrinkage methods for variable selection based on their loss structure making it
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quickly implementable with current software. The authors suggest the loss function
Ln,φ (β, γ) = 1
n
n∑
i=1 [Yi − φ (Xi;γ) − βT X˜i {Ai − α (Xi)}]2
where n is the number of observations, Yi is the ith patient’s outcome, Xi is the ith
patient’s prognostic variables, X˜ = (1,XT )T , Ai ∈ {−1,1} represents the dichotomous
treatment choice, α(x) denotes the propensity score, and φ is an arbitrary function
with a constant model for φ ∶ φ(x;γ) = γ and a linear model for φ ∶ φ(x;γ) = γT x˜.
This characterization of the loss function increases simplicity in adopting shrinkage
penalties for variable selection. Employing the adaptive lasso penalty (or, alternatively,
the SCAD or minimax concavity penalty) the solution is the β which satisfies
min
β
Ln,φ(β, γ˜) + λn p+1∑
j=1wj ∣βj ∣
where λn is a tuning parameter and wj are the weights such that w−1j = ∣β˜j ∣ is used.
Aside from estimating the optimal DTR, these β values are used to determine which
variables are important in selecting the optimal DTR such that the important variables
are those with nonzero coefficients.
Variable selection is an important part of estimating optimal DTRs because a
parsimonious selection of tailoring variables will make the estimation faster and more
reliable. Three methods have been presented here for these purposes, but more method-
ology has been published. It is imperative to use a selection technique that is relevant
for the data set and can be effectively integrated into the analysis plan.
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2.5 Analysis Techniques: Single Stage
The list of methodology presented here and in the subsequent section is neither
complete nor representative of all available options, but a simple summary of recent or
relatively recent methods employed along a broad range. The purpose is to introduce
popular techniques, highlight advancements, and display a plethora of methodological
options applicable in multiple areas of interest.
Important notation must be introduced so that an individualized treatment rule
(ITR) for the single stage paradigm can be properly defined. An ITR differs from a
DTR in that it is the personalized rule for a single treatment setting while a DTR
is the sequence of decision rules for a multiple treatment setting. Assuming the data
is collected from a single stage two arm trial, the treatments will be annotated as
A ∈ {−1,1}. These are independent of the patient prognostic variables denoted as
X = (X1, . . . ,Xp)T , where X is a p-dimensional matrix. In the single stage paradigm
the observed clinical outcome, Y , can be considered a reward function where larger
values are desired. The ITR is a map from the prognostic variable space, X, to the
treatment space, A, and the optimal ITR is the A which maximizes the expected reward.
The distribution of (X,A,Y ) is denoted by P with the respective expectation denoted
as E. The distribution of (X,A,Y ) given the ITR, D (i.e. that A =D(X)), is denoted
as PD and the corresponding expectation as ED. The expected reward under D is
V (D) = ED(Y ) = E [I {A =D(X)}
Api + 1−A2 Y ]
where pi = P (A = 1). This V (D) is referred to as the value function for a given D. The
optimal ITR, denoted D∗, is estimated as:
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D∗ ∈ argmaxDV (D) = argmaxDE [I {A =D(X)}
Api + 1−A2 Y ]
and is considered the D which maximizes the value function V (D). The optimal
treatment regime is defined as the one that maximizes the average expected outcome
(Zhao et al. 2012).
One way to estimate ITRs is to restructure the estimation procedure into a clas-
sification problem where the optimal classifier corresponds to the optimal treatment
decision. The optimal classifier can be found by estimating the Bayes classifier, which
is the one that minimizes the expected weighted misclassification error. This frame-
work allows for estimation of mean outcomes under existing methods such as regres-
sion estimation, inverse probability weighted estimation (IPWE) or augmented inverse
probability weighted estimation (AIPWE) (Zhang et al. 2012a). The class of treatment
decisions is data driven because it is chosen by minimizing the L1 the expected weighted
misclassification error and does not need to be prespecified.
Define the contrast function as
C(X) = µ(1,X) − µ(−1,X)
which can be thought of as the mean difference between treatment options for a given
set of prognostic variables. The optimal ITR estimation problem can be transformed
into a weighted classification problem such that the optimal treatment rule D∗ is found
by
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D∗ = argmaxDE [D(X)C(X)] = argmaxDE (∣C(X)∣ [I {C(X) > 0} −D(X)]2)
This means that the optimal treatment rule, D∗, is found to be the one that maxi-
mizes E (∣C(X)∣ [I {C(X) > 0} −D(X)]2), which is a weighted classification problem.
Each subject belongs to two classes such that class Z = 1 contains those subjects
who would benefit more from treatment A = 1 as opposed to treatment A = −1, e.g.
µ(1,X) > µ(−1,X), and Z = 0 the opposite. Each observation is also given a weight,
W = ∣C(X)∣, which is the loss that would incur from misclassification. Hence, the
optimal ITR is simply the expected weighted misclassification error under the classifi-
cation rule D(X). Within this classification construct, the problem then decomposes
into two critical steps. First, one must construct a suitable estimator of the contrast
function, using regression, and then invert this to find the estimated optimal treatment
rules with an interpretable form using classification methods. This can be extended
to the multiple stage scenario as well. This classification prospective falls under the
machine learning umbrella. Machine learning, most specifically reinforcement learning,
has recently been implemented since it sidesteps the problem of completely modeling
the underlying generation model as is necessary in some estimation techniques. Rein-
forcement learning is a dynamic programming system that decides which actions need
to be taken to optimize a given reward.
Qian and Murphy (2011) propose a modification of this which first estimates the
conditional mean response using l1 penalized least squares (l1-PLS) with a rich linear
model and then uses that to derive the estimated treatment rule. If the conditional
mean is modelled correctly, this method consistently estimates the optimal treatment
rule. The finite sample upper bounds of the difference between the mean response
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from the optimal treatment rule and the mean response from the estimated treatment
rule holds even if the linear model for the conditional mean response is incorrect. If
the part of the conditional mean model involving the treatment effect is correct then
the upper bounds imply that the estimated treatment rule is consistent. These upper
bounds can also inform how to choose the tuning parameters involved in the l1-penalty
to create the best rate of convergence. To obtain the ITR the estimated prediction
error is minimized then the conditional mean model is maximized over the treatment
A. To control for overfitting, l1 penalized least squares is implemented since the l1
penalty innately does variable selection. The resulting treatment rules are cheaper to
implement and easier to interpret.
The forgoing methods are considered indirect methods of estimation. Indirect
estimation refers to techniques that first estimate a quantity reflecting the conditional
distribution of the outcome, such as conditional mean, and then uses the resulting model
to deduce the optimal ITR (Laber et al. 2014c). Indirect estimation can be desirable
because the initial estimation regarding the outcome can be built using traditional
statistical modelling techniques. Unfortunately, optimal ITR estimation requires that
the conditional outcome be modelled correctly. Indirect methods of estimation often
and easily experience model misspecification because of the difficulty of modelling high
dimensional, time dependent factors. In high dimensional situations the two-step pro-
cedure of estimation and maximization equations can be poor fits. In contrast, direct
methods of estimation are solutions to the problems proposed by these other techniques
which directly achieves this maximization without requiring the initial estimation step
be done with indirect approaches. This direct class of methods immediately estimates
the value function for all prespecified treatment rules and then obtains the optimal
treatment rule by maximizing the estimator. Direct estimation methods tend to pro-
duce treatment regime estimates that are more precise than indirect methods in the
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single stage setting due to the associated reduced bias (Zhao et al. 2012).
Zhang et al. (2012b) approaches estimating dynamic treatment rules by assuming
a posited regression model. This defines the class of treatment rules while recognizing
that it is possible for the model to be misspecified. The optimal treatment regime
is estimated by directly maximizing the estimator for the overall population mean
outcome under all possible specified treatment plans using a suitable inverse probability
weighted estimator. When using observational data, this estimator has the ability to
control for possible confounders by estimating propensity scores and exploiting the
predicted outcome, which ensures precision of the estimate. Let D∗ be the optimal
treatment decision, which is the one that corresponds to the largest value of E [Y ∗(D)],
where
Y ∗(D) = Y ∗(1)D(X) + Y ∗(−1) {1 −D(X)}
is the potential outcome. The potential outcome is the outcome that would be observed
if a randomly chosen patient were to receive treatment regime D. Consider treatment
rules of the form Dη(X) =D(X,η) in the class of all possible treatment rules which is
indexed by η and will contain D∗ if µ(A,X;β) the posited regression model is correctly
specified. Therefore, estimating η∗ = argmaxηE [Y ∗(Dη)] and defining D∗η = D(X,η∗)
will provide an estimator for D∗. To estimate E [Y ∗(Dη)], an IPWE or a doubly robust
AIPWE can be employed. This estimator is directly maximized in η to obtain an η∗
and hence Dˆ∗η(X) = D(X, ηˆ∗). This can easily be extended to the multiple decision
situation by estimating Q(η) = E [Y ∗(Dη)] as a function of η.
Direct methods of estimation can also be restructured into a classification problem
which can utilize computer science techniques. This looks at the data by comparing the
27
difference between subjects with observed high and low rewards so that the determina-
tion of the actual treatment decisions is associated with the actual treatments received
for the different groups. This method is referred to as outcome weighted learning
(OWL or O-learning). Developed by Zhao et al. (2012), O-learning is a nonparamet-
ric approach which directly optimizes the value function V (D) where each subject is
weighted proportional to their clinical outcome divided by the propensity score, which
is the probability of receiving the assigned treatment given the covariates. In the case
of a clinical trial, the propensity simplifies to the constant probably of receiving the
assigned treatment. Finding the D∗ that maximizes V (D) = E [ I{A=D(X)}
Api+ 1−A
2
Y ] is equiv-
alent to finding the D∗ that minimizes V¯ (D) = E [ I{A≠D(X)}
Api+ 1−A
2
Y ] which sets the stage
to view this as a weighted classification error. Minimizing the previous expected value
can be approximated by minimizing
n−1 n∑
i=1
Yi
Aipi + 1−Ai2 I [Ai ≠ sign{f(Xi)}]
to find the optimal f∗ and then setting
D∗(x) = sign{f∗(x)}
since D∗(x) can always be represented as sign{f∗(x)}. This implies the goal is to find
a decision rule which chooses treatments based on their specific prognostic variables.
On average, patients with large rewards will be recommended the same treatment that
they actually received while patients with small rewards will receive the opposite. This
is considered 0-1 loss in the machine learning scenario and is difficult to minimize due
to non-convexity and discontinuity. This problem is alleviated by transforming the
problem, using a surrogate for the 0-1 loss, so that the goal becomes minimizing
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n−1 n∑
i=1
Yi
Aipi + 1−Ai2 {1 −Aif(x)}+ + λ∣∣f ∣∣2
where x+ = max(x,0), and ∣∣f ∣∣ is the norm of f . Therefore, this problem is now
a weighted classification problem that can be solved using support vector machine
methods.
O-learning has many applications but there are also many ways to extend this line
of thinking. Chen et al. (2016) presented a one stage clinical trial design for penalized
dose finding using a robust analysis method based on the O-learning framework. The
method converts the individualized dose selection problem into a penalized weighted
regression with truncated l1 loss. The dose level is assumed to be found on a contin-
uum and a non-trivial extension of O-learning for binary treatments is proposed. The
dose finding problem becomes a weighted regression with random outcome where the
individual responses are the weights. In the linear case, this framework has the goal of
minimizing the loss plus penalty of the form
min
f
{ 1
n
n∑
i=1
Rilφ {Ai − f(Xi)}
2φnp(Ai∣Xi) + λn∣∣f ∣∣2}
where φ = φn is non-random parameter in real space, λn controls the severity of
the penalty on f , lφ {Ai − f(Xi)} = min ( ∣A−f(X)∣φ ,1), R∗(a) is the potential outcome
and R = ´ I(A = a)R∗(a)p(a∣x)da. The complexity of f(x) is penalized to prevent
overfitting. This function is nonconvex and hence difficult to optimize, so an adaptive
difference convex (DC) algorithm is implemented (Tao and An 1997). Considering a
linear loss function, the objective function is
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S = λn
2
∣∣w∣∣22 + 1φn n∑i=1Ri min(∣Ai =D(Xi)∣φn ,1)
where λn is now the tuning parameter. This algorithm minimizes the sequence of
convex sub-problems with the intent of solving the original non-convex minimization
problem. Therefore, the convex sub-problem becomes a weighted penalized median
regression problem. Ultimately, the algorithm concludes when ∣∣wt+1 − wt∣∣ is smaller
than some prespecified constant, where w = ∑i∈T (αi − α¯i)xi. Expanding to the nonlin-
ear framework, the decision function then becomes a function of w and some unknown
transformation on X. A Gaussian kernel is used to construct a dual problem for nonlin-
ear learning that is solved using quadratic programming. To practically implement this
procedure, a nonconvex loss function and a DC algorithm for optimization is employed.
Another common and extremely relevant application of O-learning is estimating
ITRs for censored data. Realistically many chronic diseases measure short term success
of a treatment as a failure or success. It is desirable to develop methods of estimating
treatment regimes that are applicable to survival analysis because it has clear relevance
to personalized medicine. When considering censored data, notation is slightly altered.
The value function is redefined as
V (D) = ED(T ) = E(T ∣X,A =D(X)) = E [I {A =D(X)}
Api + 1−A2 T]
where T =min(τ, T˜ ) where T˜ is the survival time and τ is the end of the study (Zhao
et al. 2015). Even though the outcome is redefined, the optimal treatment rule is still
the treatment rule which maximizes the value function. The goal is to estimate D∗
using censored data following the OWL framework. There are two approaches to esti-
mation. First, one can maximize the estimator of the average survival time. To account
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for right censoring, the estimated mean survival time is reassigned as the weighted mis-
classification rate. These weights are comprised of both the observed outcome and the
inverse probability of censored weights. To offset bias from a misspecified censoring
model, a second method, a doubly robust variation of outcome weighted learning, is
formulated. In both instances, the treatment rule is consistent for the optimal rule when
the model for either the survival times or censoring times is correctly specified. Note:
it is not required that both models be correctly specified. A convex relaxation idea
from support vector machines is invoked for construction of the necessary estimation
algorithm.
The methodological techniques available for estimating ITRs in the single stage
scenario encompass a broad spectrum. Some of these techniques have been extended
to apply to the estimation of DTRs but not all have, making this an important area of
future work. Because of the nature of sequential decision making, some of the associated
techniques cannot easily be extended beyond the single stage setting, so it is important
to continue making progress in both areas.
2.6 Analysis Techniques: Multiple Stages
There is a lot of interest and value in the practicality of creating techniques
which accurately estimate optimal DTRs. The multiple stage scenario most similarly
mimics the natural course of a chronic disease. Considering patients often need multiple
treatments, individuals respond differently to different treatments at different points in
their progression, and the longevity of the disease can be unknown, these techniques
are important for an adequate treatment plan.
In order to properly define DTRs in this setting, notation will be presented that
expands on that which is used in the single stage paradigm. Consider a trial with
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T decision points. For t = 1, . . . , T , let At ∈ {−1,1} be the dichotomous treatment
assignment at the tth stage and Xt be the patients’ prognostic variables before the tth
decision point but after the At−1 treatment assignment. The outcome, or reward, at the
tth stage is Yt where larger values are assumed more desirable. Yt is assumed to depend
on all previous prognostic information (X1, . . . ,Xt), all treatment history (A1, . . . ,At)
and previous outcomes (Y1, . . . , Yt−1). The overall outcome of interest is the total reward∑Tt=0 Yt. The DTR is then a set of sequential decision rules D = (D1, . . . ,Dt) which maps
from total patient history, Ht = (X1,A1, . . . ,At−1,Xt) to the treatment space. The value
function is then defined as
V (D) = ED [ T∑
t=1Yt]
where ED is the expectation under the measure PD which is the distribution for
(X1,A1, Y1, . . . ,XT ,AT , YT ,XT+1) for some DTR D. The value function is the
expected long term benefit if the population were to follow regimen D and can also be
defined as
V (D) = E ⎡⎢⎢⎢⎢⎣
(∑Tt=1 Yt)∏Tt=1 I {At =Dt(Ht)}∏Tt=1 pit(At,Ht)
⎤⎥⎥⎥⎥⎦ .
Similar to the single stage situation, the value that maximizes the value function V (D)
D∗ ∈ argmaxDV (D)
is the optimal DTR D∗ (Zhao et al. 2014).
One of the most popular indirect methods of estimation is a computer science
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method called Q-learning (Watkins and Dayan 1992). Q-learning is a form of reinforce-
ment learning and is a dynamic programming procedure that uses backwards recursion
to solve the complex Bellman equation more efficiently using regression models. In the
two stage setting, Q-functions are defined as
Q2(h2, a2) = E [Y ∣H2 = h2,A2 = a2] , Q1(h1, a1) = E [max
a2
Q2(h2, a2)∣H1 = h1,A1 = a1] .
The Q-functions are conditional expectations where Q2(h2, a2) evaluates the quality of
choosing treatment a2 for patients with history h2 and Q1(h1, a1) evaluates the quality
of choosing treatment a1 for patients with history h1 assuming that the best second
stage intervention has chosen. This can be extended to more than 2 phases such that
Qt(ht, at) = E [max
at
Qt+1(ht+1, at+1)∣Ht = ht,At = at]
would evaluate the quality of choosing at for patients with history ht assuming the best
intervention is chosen at all future stages. In practice, these Q-functions are not known
but are estimated using a linear form
Qt(ht, at) = hTt,1βt,1 + athTt,2βt,2.
In the two stage scenario, estimating the Q-functions, Qˆt(ht, at), is a three step
procedure. First, using ordinary least squares regression, the estimates βˆ2,1 and βˆ2,2 are
obtained by regressing the patient history on Y2. Those estimates are used to estimate
the fitted Q function at the second stage Qˆ2(h2, a2) = hT2,1βˆ2,1 + a2hT2,2βˆ2,2. The stage 1
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pseudo outcome is Y˜1 = Y1+maxa2 Qˆ2(h2, a2). Note that if the outcome is only collected
at the final stage (in other words, there is only one Y so there is no Y2, Y1), the stage 2
outcome is Y and the stage 1 psuedo outcome is Y˜ = maxa2 Q˜2(h2, a2). The first stage
patient history is regressed on Y˜1 to obtain the estimates βˆ1,1 and βˆ1,2. The first stage
fitted Q function is Qˆ1(h1, a1) = hT1,1βˆ1,1 + a1hT1,2βˆ1,2. Finally, the estimated optimal
treatment decision is given by
D∗t (ht) = argmaxatQˆt(ht, at).
Estimating the Q-functions is similar for three or more stage implementation where
the predicted future outcome is used to create the estimates for the previous stage
estimated Q-function.
While Q-learning is a very popular estimation technique, it is not without its
limitations and suffers from some undesirable properties such as nonregularity, non-
smoothness and asymptotic bias (Robins 2004). A nonregularity problem occurs in
Q-learning when the last stage treatment is non-unique for some subjects in the pop-
ulation. This causes bias and inaccurate inference, causing the Q-functions to take
non-linear forms. To remedy this, Goldberg et al. (2013) uses special adaptive weights
within the penalization. This corrects for the non-regularity condition by concentrat-
ing on the indifference hyperplane of patient covariates where two treatment have the
same effect. The indifference hyperplane is the covariate region where there is no dif-
ference between treatments. Solving this non-regularity condition involves correctly
identifying the covariate values which lie on this hyperplane. This adaptive penalized
Q-learning procedure can handle continuous covariates and performs better than the
penalized Q-learning method. Unfortunately, it can only be implemented with discrete
covariates.
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Instead of the typical first stage of Q-learning (which involves solving the mini-
mization problem) the adaptive minimization problem involves solving
Φ2n(θ2) = n∑
i=1 {Y2i −Q2(h2i, a2i;β2,1, β2,2)}2 − λnn n∑i=1 ωˆni∣β′2,2H2i(2)∣
where ωˆni are the data driven weights and λn is the tuning parameter. Then, θ˜2
(in traditional Q learning this is the set of parameters which minimizes the ordinary
least squares regression function at the second treatment decision time point) is the
minimizer of Φ2n and the remaining steps of Q learning are the same after substituting
in θ˜2 for the normal estimator. In order to obtain the oracle property (which means
the estimator behaves asymptotically as if the indifference place is already known) the
selection of weights is critical. The goal is to find weights that penalize the observations
that are close to or are on the indifference hyperplane and that provide weights that go
asymptotically to zero for observations far from the hyperplane. This will help define
where the indifference hyperplane is and resolve the non-regularity problem.
As in most statistical research areas, after developing an estimator the next step
is to assess its properties, oftentimes with the use of inference techniques such as con-
fidence intervals. When estimating optimal DTR, common approaches such as Q-
learning involve estimation and interference of parameters that are non-smooth func-
tions of the underlying generative distribution. As was mentioned before, these esti-
mates are non-regular and asymptotically biased. Standard asymptotic approximations
to the sampling distributions cannot be used to directly form reliable confidence inter-
vals or carry out hypothesis testing (Laber et al. 2014c). One method to construct
confidence intervals is an m-out-of-n bootstrap procedure to correct the nonsmooth-
ness. The confidence sets are constructed in a way to adapt to the nonregularity
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present in the underlying generative model. The data driven adaptive choice of m pro-
duces asymptotically correct confidence sets under fixed alternatives. This method has
the added benefit of conceptual and computational simplicity with a corresponding R
package (Chakraborty et al. 2013).
The proposed adaptive scheme to select m is a class of resample sizes given by
m = nf(p). The suggested simple form is proposed to be
mˆ = n 1+α(1−pˆ)1+α
where α > 0 is a tuning parameter. α controls the smallest acceptable sample size
and may be dictated by practical considerations or tuned using the data. A bootstrap
algorithm is used for choosing α using data which appears to reduce conservatism.
When the parameter of interest is a linear function of the parameters, (c′θ1,n), the
algorithm first draws B1 m-out-of-n first stage bootstrap samples and estimates cT θˆb11,n.
α is fixed at the smallest value in the grid. mˆb1 is then calculated using the equa-
tion above. Repeat this drawing B2 mˆb1-out-of-n second stage bootstrap samples and
calculate cT θˆ(b1,b2) which is a double bootstrapped version of the estimate. For all b1,
compute (η2)x100 and (1 − η2)x100 percentiles which are the lower bounds and upper
bounds defined as lˆb1DB and uˆ
b1
DB respectively. The coverage rate of the double bootstrap
confidence interval from all first stage bootstrap data sets is
1
B1
B1∑
b1=1 I (cT θˆb11,n − uˆ
b1
DB√
mˆb1
≤ cT θ1,n ≤ cT θˆb11,n − lˆb1DB√
mˆb1
) .
Increase α to the next highest value on the grid until the coverage rate is at or exceeds
the nominal value and in that case pick the current value of α as the final value. The
process is repeated until the coverage rate of the double bootstrap confidence interval
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attains a nominal coverage rate or all the options on the grid are exhausted.
Another methodology that can accommodate the non-regularity from using Q-
learning to estimate parameters is the locally consistent Adaptive Confidence Interval
(ACI) (Laber et al. 2014c). When construction of DTRs using Q-learning, there is par-
ticular interest in reducing bias of first stage coefficients. If the Q-function is near 0 with
high probability there will be issues approximating the distribution of
√
n (βˆ1 − β∗1 ).
Once the asymptotically biased parameters are identified, given the correct amount
of shrinkage, a shrinkage estimator can reduce the bias. However, shrinking too ag-
gressively leads to bad performance in finite samples. Constructing valid confidence
intervals for non-regular estimators is a difficult task because estimating the sampling
distribution of the estimator cannot be done uniformly. The proposed solution is a lo-
cally consistent confidence interval for linear combinations of the first stage coefficients.
The interest is not in construction of second stage confidence intervals because they
can be estimated using standard methods for least square estimators. Since it is not
possible to construct a uniformly convergent estimator of the limiting distribution of√
n (βˆ1 − β∗1 ), for a given constant c the proposed method bounds cT√n (βˆ1 − β∗1 ) be-
tween two regular uniformly convergent upper and lower bounds. These smooth bounds
can be bootstrapped to form a confidence set for cTβ∗1 . The extension to more than
two stages is straightforward as the last stage uses standard methods for least squares
estimation, so the ACI would be used on all previous stages.
Similar to previously discussed analysis techniques, for medical research it is im-
portant to develop these techniques to accommodate censored data. Goldberg and
Kosorok (2012) developed a Q-learning algorithm that allows for censored data when
the outcome of interest is survival time and allows for a flexible number of stages in a
randomized trial. Q-learning is expanded upon by using inverse probability censoring
weighting to account for censored observations.
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For each t = 1, ..., T , let the state St be the pair St = (Xt, Yt−1) where Xt is either
a vector of covariates describing the condition of the patient before time t or it is null.
If Xt is null then a failure happened during the tth stage. Let Yt−1 be the length of time
between decision points t and t−1. Hence, ∑tj=1 Yj is the total survival time, or reward,
up to and including stage t. Let C ∈ [0, τ] be the censoring variable. The goal is to
find a policy that maximizes the expected rewards. Then, the optimal policy, D∗, is
the one that approximately maximizes over all policies of E0,pi [(∑Tt=1 Yt) ∧ τ] where T¯ is
the random number of stage for the subject. This optimal policy is found using a three
step algorithm. First the problem is mapped to an auxiliary problem. The auxiliary
problem creates modified trajectories of a fixed length T and the modified sum of the
rewards is less than or equal to τ to account for censoring. Next, the Q-functions are
approximated {Qˆ1, ..., QˆT} using the original Q-function framework. Last, the optimal
treatment rule, D∗, is found by maximizing Qˆt over all possible at.
Recall the methodology introduced in the previous section for estimation of ITRs
in a single stage. Two of those methods will be expanded on when estimating DTRs for
multiple stages of treatment. In the single decision scenario presented by Zhang et al.
(2012b) the estimation procedure was restructured into a classification problem. In this
case the optimal classifier corresponds to the optimal treatment decision. The optimal
classifier was found by estimating the Bayes classifier which is the one that minimizes
the expected weighted misclassification error. This can be expanded upon for the two
decision point scenario based on reassessing the problem as a monotone coarsening prob-
lem using an augmented inverse probability weighted estimator (AIPWE) to estimate
the mean outcome (Zhang et al. 2013). Assign Y ∗ to be the often unobserved potential
outcome and Y ∗D to be the potential outcome associated with treatment regime D. The
optimal treatment regime D∗ is that which satisfies E [Y ∗(D∗)] ≥ E [Y ∗(D)] meaning
it is that which maximizes the expected potential outcome. The problem is cast into a
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monotone coarsening problem where the coarsening happens at random if, for each t,
the probability that the data are coarsened at level t given the full data depends only
on the data observed at level t. Then, from Robins et al. (1994), under these coarsening
assumptions if the coarsening mechanism is correctly defined then asymptotically linear
consistent estimators for E [Y ∗(Dη)] for a fixed η have the form
∑ni=1 I(Cη,i =∞)
Kη,kX¯k,i
Yi + ∑ni=1 {I(Cη,i = k) − λη,k(X¯k,i)I(Cη,i > k)}
Kη,k(X¯k,i) Lk(X¯k,i)
where Lk(X¯k,i) are arbitrary functions, Cη,i is the discrete coarsening variable,
Kη,K(X¯K) =∏kk′=1 {1 − λη,k′(X¯k′)} and λη,k′(X ′k) is the hazard function. The left side of
the above estimator is on its own a consistent estimator if λη,k(X¯k) is correctly specified.
Then the entire estimator is a doubly consistent robust estimator for E [Y ∗(Dη)] if
either λη,k(X¯k) are correctly specified or if Lk(X¯k,i) = Y ∗(Dη)∣ {X¯∗k (D¯ηk−1) = x¯k}.
O-learning was presented as a machine learning approach which directly optimizes
the value function V (D) where each subject’s weight is proportional to their clinical
outcome. This is a weighted classification error problem since finding the D∗ that
maximizes V (D) is equivalent to finding the D∗ that minimizes V¯ (D). O-learning can
also be expanded to the two stage paradigm using a few strategies. One such way is
backwards outcome weighted learning (BOWL) which modifies existing algorithms to
solve a sequence of weighted classification problems (Zhao et al. 2014). The algorithm
is backwards fitting and at each time point T , the algorithm is as follows. The goal in
the first stage is to minimize
n−1∑ni=1 [YiTφ{AiTfT (HiT )}]
piT (Ait,Hit) + λT,n∣∣fT ∣∣2
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with respect to fT where fˆT is the minimizer. The optimal decision rule is
DˆT (hT ) = sign{fˆT (hT )} ,
and this stage is essentially equivalent to the single stage outcome weighted learning
found in Zhao et al. (2012) and has a similar dual objective function as found in support
vector machines. The second stage is, for t = T−1, T−2, . . . ,1, to backward sequentially
minimize
n−1 n∑
i=1
(∑Tj=1 Yij)∏Tj=t+1 I {Aij = Dˆj(Hij)}∏Tj=1 pij(Aij,Hij) xφ{Aij, ft(Hit)} + λt,n∣∣ft∣∣2
where Dˆt+1, . . . , DˆT are previously obtained.
A disadvantage of BOWL is the number of observations utilized by the algorithm
decreases geometrically as t decreases. The authors explain this can be solved using
iterative outcome weighted learning (IOWL) which involves re-estimating the optimal
treatment rule at stage 2 after the stage 1 rule is estimated. This estimate is based
on the subset of patients whose stage 1 treatment assignments are consistent with
the optimal rule. The procedure would continue with a re-estimation of the stage 1
treatment rule based on the new optimal stage 2 rule. IOWL allows the exploration of
different subjects through iterative re-estimation.
Zhao et al. (2014) also present simultaneous outcome weighted learning (SOWL)
which frames estimation of DTRs as a single classification problem. This is an effective
way of looking at the problem because a multiple stage treatment plan has not pre-
viously been estimated simultaneously using a single algorithm. The method directly
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optimizes the empirical counterpart of the value function in one step. Since this prob-
lem is computationally difficult (mostly because of the discontinuity of the indicator
functions) a continuous and concave surrogate function is used in lieu of the product of
indicators that would usually be required. In the two decision point scenario, the surro-
gate reward function is chosen to mimic hinge loss: ψ(Z1, Z2) =min(Z1−1, Z2−1,0)+1
where Z1 = A1f1(H1) and Z2 = A2f2(H2). Hence the SOWL estimator maximizes
n−1 n∑
i=1
(∑2j=1 Yij)ψ {Ai1f1(Hi1),Ai2f2(Hi2)}∏2j=1 pij(Aij,Hij) − λn(∣∣f1∣∣2 + ∣∣f2∣∣2),
where the tuning parameter λn controls the amount of penalization. This can easily be
extended to more than 2 stages.
Much exciting and significant work is being done in developing treatment rules
with the intent of dynamic sequential decision making. To this effect, there have been
promising advancements, but these methods often times need to be expanded upon
or adapted to various specific settings. Science will forever be changing and the best
everyone can hope to do is keep up. While existing methodology can always be improved
and generalized, at the same time there will probably never be a lack of need for new
and innovative mechanisms for estimating optimal DTRs.
2.7 Observational Data
As clinical researchers were experimenting with new trial designs to improve pa-
tient treatment plans, epidemiologists were simultaneously investigating the relation-
ships of time varying continuous exposures to various outcomes in observational data
(Lavori and Dawson 2014). They developed a longitudinal generalization of Rubin’s
potential outcomes (Holland 1986) for inference between exposure and outcomes for
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observational data which naturally led to an interest in developing DTRs for this data.
These methods include G-estimation, non-parametric theory and methods designed to
handle large mathematical combinations of observational treatment regimes. These
treatment plans are germane for clinical patient treatment because these DTRs assume
the exposures are assigned in a way that is conditionally independent of the potential
future responses given the history of the patients and treatments up to the current
state. This resembles the assumptions made when developing treatment plans using
randomized prospective data.
Randomized trials have been regarded as the optimal way to test any treatment,
so why would it be a good idea to use observational data to develop and determine the
optimal DTR instead of designing a SMART? Often times situations arise where a ran-
domized trial is impossible or impractical, so it is efficacious to perform an observational
study instead. Additionally, observational data may exist from a preexisting study. Us-
ing this resource can be more expedient and reduce significant financial burden because
new patients are not needed and no treatments are given. The development of DTRs
is often exploratory and hence it is potentially important to be able to estimate these
treatment plans using large samples of observational data with the intention of validat-
ing the DTR in a confirmatory randomized trial. Furthermore, collecting observational
data on time-varying outcomes, predictors and confounders can sometimes emulate a
randomized trial that lacks baseline randomization.
An effective estimation technique when eliciting DTRs from observation data
is the parametric g-formula. The parametric g-formula uses Robins’ G-estimation to
naturally estimate DTRs and can appropriately adjust for time-dependent cofounding
variables (Young et al. 2011). This formula is an alternative to inverse probability
weighting that provides more efficient estimates but requires more parametric modelling
assumptions. When using low dimensional data, the g-formula is
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∑
lk
k∑
j=0P (Yj+1 = 1∣Lj = lj,Aj = aDj , Y¯j = Cj+1 = 0)
× j∏
s=0[P (Ys = 0∣Ls−1 = ls−1,As−1 = as−1, Ys−1 = Cs = 0)× f(ls∣ls−1, as−1, Ys = Cs = 0)]
where Yj represents the indicator of death by the end of time j, Lj represents the
last measurements of covariates preceding treatment assignment, Aj indicates treat-
ment before time j, and Cj indicates censorship status by the end of time j such that
P (Ys = 0∣Ls−1 = ls−1,As−1 = as−1, Ys−1 = Cs = 0) is the probability of surviving through
month s conditional on not being censored through s, surviving through s−1 and ad-
hering to the designated treatment regime through j−1 for the specific history (Lj,Aj),
f(ls∣ls−1, as−1, Ys = Cs = 0) is the density for Ls conditional on not being censored and
survival through s and adhering to the designated treatment regime through j−1 for the
specified history. It can be computed for the potential outcome by non-parametrically
estimating the value of each density function for all of the possible histories of patients.
The formula takes the sum over the histories but requires that all possible covariates
need to be categorical. For high dimensional data, the g-formula can only be carried out
by estimating the density functions using parametric modelling assumptions then tak-
ing the sum over the histories via Monte Carlo simulation. Because of distributional a
priori knowledge for certain histories, when estimating the g-formula parametric models
are not needed to be imposed over all components of the densities and histories.
While there has been progress using g-estimation for estimating optimal DTRs,
there exists limited methods to check the model performance and validate assumptions.
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Fortunately, Rich et al. (2010) developed a method for g-estimation model checking di-
agnostics that uses traditional tools when evaluating DTRs. With the goal of assessing
the model examining a residual plot, a new residual is proposed that redefines a fitted
Yˆi (since the residual is defined as Yi − Yˆi). The authors propose
Yˆij(ψ) = E [Hij ∣L¯j, A¯j−1; ξ(ψj)] − K−1∑
m=j+1µm(ψm) + γj(ψj)
where ψ is the blip parameter, L is the history, H is interpreted as the difference
between removing the effect of the treatment from the outcome and adding the effect
of making the optimal treatment decisions in the future, µ is the effect of the optimal
treatments in the future, γ is the blip function, and ξ is a nuisance parameter. The
blip function is a functional form of the mean difference in responses under two possible
actions conditional on the patients’ history. The estimates of ψˆ and ξˆj(ψˆj) from the G-
estimation procedure can then be plugged in to obtain a usable fitted outcome. Then,
the residual can be as usual: rij = Yi − Yˆij(ψˆ). These residuals can be used to diagnose
underlying specification problems in the blip and expected potential outcome models
and check linearity assumptions. The residual plots can be visually assessed as usual
where a good model will have a symmetric distribution around zero and no trend when
plotted against covariates or fitted values.
G-estimation in the context of estimating DTRs has advantages over traditional
parametric approaches for producing consistent estimators. However, these estimators
are asymptotically biased under a given structural nested mean model for certain data
distributions (coined exceptional laws) and exhibit non-regular behavior. To combat
this, Moodie and Richardson (2009) presented a new approach called Zeroing Instead
of Plugging In (ZIPI). ZIPI provides estimators nearly identical to those provided by
g-estimation but with the benefit of reducing bias in those situations when decision
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rule parameters are not shared across intervals. More specifically in the context of
constructing DTRs, the observed longitudinal distribution function is “exceptional” if
at some interval there is a positive probability that the true optimal decision rule is not
unique. For a distribution to be exceptional, the blip function must include at least
one covariate (such as the previous treatment), and the probability that the true blip
function has value 0 is positive. The proposed ZIPI method is considered a modification
of g-estimation when there is no parameter sharing and detects and reduces bias in the
presence of exceptional laws. Bias is found in the g-estimating equation of ψ1 by
including the upwardly biased estimate of
I {g2(L¯2,A1;ψ2) > 0} g2(L¯2,A1;ψ2)
into the g-estimating equation when g2(L¯2,A1;ψ2) is close to 0. The proposed algorithm
searches for individuals who will likely have g2(L¯2,A1;ψ2) = 0 and then uses the best
guess of zero instead of the estimate obtained by plugging in ψ2. Hence, it uses an all or
nothing weight system which either applies weights 0 or 1 depending on the estimated
unique rule class membership. This method is considered a class of pre-test estimators
frequently used in statistical analysis. ZIPI requires testing all the individuals at all
intervals except the first ones which creates a concern about potentially reduced power.
What about modifying preexisting techniques developed for randomized data to
be used on observational data? Instead of developing an array of new techniques, is
it possible to alter portions of those methods so they are applicable for observational
data? Unfortunately, the answer to that question is unclear as this has not been a
well-studied area. However, Moodie et al. (2012) extended one of the more frequently
utilized methods of optimal DTR estimation, Q-learning, to accommodate observational
data. A soft threshold approach is used which has a good performance in terms of bias
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and coverage in the non-regular settings. This approach shrinks the problematic term
in the potential outcome towards zero. In the Q-learning algorithm this would replace
the potential outcome with
Yˆ ST1,i = βT2 H20,i + ∣Ψˆ2H21,i∣ ⋅ {1 − ( λi∣ΨˆT2H21,i∣2)
+} ,
where λ is a data driven tuning parameter. λi is chosen using a Bayesian approach
where λi = 3HT21,iΣ2H21,i/n and Σ2 is the estimated covariance matrix of Ψˆ2. The rest
of the Q-learning algorithm stays the same.
When using Q-learning for observational data, the basic approach requires the
construction of a propensity score, pi(x) = P (A = 1∣X = x), or treatment model followed
by some form of adjustment. It assumes the treatment received is independent of known
covariates given the propensity score. This leads to unbiased estimates of the treatment
effect based on the conditional expectation modelling the outcome given the propensity
score. In inverse probability weighting analysis, the weights are used to create a pseudo-
sample so that the treatment does not depend on the variables in the pseudo-sample.
Including covariates into the models for the Q-functions can be implemented in four
ways which perform well: including the covariates as linear terms in the Q-function,
including the propensity score as a linear term in the Q-function, including quintiles
of the interval-specific propensity score (which depends on a time varying confounding
variable) as covariates in the jth interval Q-function, and IPTW weighted with H1 and
H2 defined as in traditional Q-learning.
Not all data can be collected using a randomized clinical trial, so it is imperative
to develop methodologies that can estimate optimal DTRs using this observational
data. This data is difficult because there is no randomization, but the assumption of
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independence between exposure and predicted future outcome simplifies the problem
to an extent. While the parametric g-formula and Q-learning are great options for
analysis, not all data will benefit from these techniques and more work would provide
more resources and flexibility for scientists.
2.8 Competing Outcomes
While development of these advanced estimation techniques is necessary to effec-
tively personalize medical care, treatment of the entire person, not just one disease,
should be considered as well. In the tangible clinical setting, the patient or caregiver
will likely be interested in balancing competing outcomes such as survival, quality of
life and financial burden. While survival may be the ultimate goal for a cancer patient,
a single mother of two may prefer a treatment that allows her to work (higher quality
of life) which could lead to a longer treatment course, or patients may need to balance
the financial burden with their treatment plan. This is a very new area of study inside
the personalized medicine umbrella, but it is important and quickly developing.
A crucial step in balancing competing outcomes for personalized patient care is
eliciting the patient’s or physician’s preferences regarding the ideal tradeoff between the
outcomes. Lizotte et al. (2012b) produced an inverse preference elicitation approach
which first considers all of the actions available at any given state. Then, for each action,
asks what range of preferences makes that action a good choice. This provides a large
amount of information about the potential actions at each state. The patients also have
the ability to see if their preference is near the boundary or see if a small change in
preference results in a change of recommended treatment. In this situation, the patient
can feel confident that both treatments perform well and make the decision based on
other potentially minor preferences. This method provides an efficient algorithm that
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computes the optimal policy for varying reward functions and provides insight into how
the choice of reward influences the optimal treatment decision.
Let Vt(ht, δt) be the value function where δt represents the patient’s preference
that can be thought of as the part of the patient’s history that doesn’t evolve with
time and does not influence transition dynamics between time points. The fixed δ
identifies each single decision process by fixing a reward function which can be viewed
as representing the patient’s preference. Vt(ht, δt) is a piecewise linear function and is
developed through a series of state t Q-functions obtained from the Bellman equation.
The exact piecewise linear representation of the value function for each history and time
point is found allowing efficient, exact computation of value backups for all δt. This
method also identifies the actions not optimal for any history or preference. These value
backups require minimization over all possible actions and expectations over all future
states. Convex hull routines provide ordered output which makes it easy to recover
the list of treatments that are optimal for each δt and what values of δt correspond to
a change in the optimal treatment strategy. These values of δt are the knots in the
piecewise linear representation and define the piecewise function. A list of knots with
their corresponding values is used instead of the list of points. The policy is found in
a list which contains the optimal corresponding actions at each knot and the optimal
policy for each stage by taking the intersection of the treatment lists for the endpoints
of the segment. A binary search for the largest knot that is less than some δt defines
which linear piece is maximized for δt and hence only that single linear function needs
to be evaluated. The piecewise linear representation of the value function Vt(ht, δt) is
used to efficiently compute a piecewise linear approximation of the Bellmen equation
by evaluation conditional expectations of Vt(ht, δt) over possible future states. This can
easily be generalized to a scenario where there are an arbitrary number of features of
state variables and where there are more than two decision points.
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Alternatively, Laber et al. (2014b) developed a way to construct DTRs that does
not require tradeoffs between outcomes by eliciting a clinically significant difference for
each respective outcome. When the algorithm concludes that no single treatment is
best, the patient’s or doctor’s preferences are able to be incorporated. They are free to
choose the treatment arbitrarily based on other qualities that matter to them, such as
cost. This method involves set-valued dynamic treatment regimes that take as input
the current patient history and provide as output a set of recommended treatments.
Considering just the static set valued decision rules for the single decision time
point, let Y and Z be the competing outcomes and ∆Y ,∆Z represent the predetermined
clinically meaningful difference in the respective outcomes. In the ideal situation, the al-
gorithm will produce one recommended treatment if that treatment provides significant
benefit to one outcome without producing significant detriment to the other. However,
in all other cases, the algorithm will produce a set of recommended treatments and the
decision is left up to the clinician or patient. With
τY (h) = E [Y ∣H = h,A = 1] −E [Y ∣H = h,A = −1]
and
τZ(h) = E [Z ∣H = h,A = 1] −E [Z ∣H = h,A = −1]
then the ideal decision rule piideal∆ (h) is either
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1. sign{τY (h)} if ∣τY (h)∣ > ∆Y and sign{τY (h)} τZ(h) > −∆Z
2. sign{τZ(h)} if ∣τZ(h)∣ > ∆Z and sign{τZ(h)} τY (h) > −∆Y
3. {−1,1} otherwise
Generalizing this procedure to dynamic set valued decision rules for two or more
decision points, the algorithm is backwards regressive and Q-learning with linear work-
ing models is used to estimate rY (h) and rZ(h). Using ordinary least squares, the
optimal treatment set can be estimated from patient history. At the second stage, esti-
mating piideal2∆ is essentially the same as described for the single decision point situation.
To find piideal2∆ , it is assumed that the best single treatment decision (not a set-valued
decision) was made, τ2. Then, piideal1∆ (h1, τ2), at the first stage is
1. sign{τY (h1, τ2)} if ∣τY (h1, τ2)∣ > ∆Y and sign{τY (h1, τ2)} τZ(h1, τ2) > −∆Z
2. sign{τZ(h1, τ2)} if ∣τZ(h1, τ2)∣ > ∆Z and sign{τZ(h1, τ2)} τY (h1, τ2) > −∆Y
3. {−1,1} otherwise
Hence, the optimal decision rule is the set valued rule
piideal1∆ (h1) = ⋃
τ2∈C(piideal2∆ )pi
ideal
1∆ (h1, τ2)
where C (piideal2∆ ) is the set of all treatment options compatible with piideal2∆ and τ2 is
compatible with pi2 if and only if τ2(h2) ∈ pi2(h2) ∀ h2.
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Progressing from estimating techniques for one outcome to multiple outcomes is
the next step in the natural course of this specialization. Practically, patients and
doctors will have more than one goal when developing a treatment plan and these
complicated preferences should be taken into consideration if possible. As this is a new
area, there is continuing progress.
2.9 Conclusion
Data collected from SMARTs is an integral part of effectively developing DTRs.
This has been a hot topic in clinical trial design in recent years and appears to be the
future of clinical practice. They are flexible, informative studies which utilize all of
the participants and can answer more questions than a traditional RCT. Pilot studies
are essential for designing a SMART so that resources are optimized and the essential
information is properly collected. While there has been progress made in properly
designing SMARTs, there is still a lot of work to be done particularly in sample size
estimation and handling missing data. A plethora of direct and indirect techniques
have been presented here to highlight some of the most current methods available so
the reader can make informed decisions when creating their analysis plan for a SMART
design or even when working with observational data. One of many future directions
in this area is practical implementation in clinical practice which involves estimating
DTRs for competing outcomes, an area which is quickly expanding. The recent progress
over the last ten years has been very exciting, but there are still many areas that could
use further development and many topics that have not been explored yet. The future
of implementing SMARTs for developing DTRs to personalize medicine is bright and
promising.
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CHAPTER 3: INCORPORATING PATIENT PREFERENCES INTO
ESTIMATION OF OPTIMAL INDIVIDUALIZED TREATMENT
RULES
3.1 Introduction
It is widely recognized that best possible clinical care is tailored to individual
patient characteristics (Sox et al. 2008, Hamburg and Collins 2010, Collins and Varmus
2015) including subjective factors like patient personal preference (Edwards and El-
wyn 2009). Individualized treatment rules (ITRs) formalize personalized clinical care
as a function from up-to-date patient information to a recommended treatment. An
optimal ITR maximizes the mean of some pre-specified clinical outcome if applied to
make treatment decisions for all patients in a population of interest. This definition of
optimality is mathematically convenient as it reduces estimation of an optimal ITR to
a scalar optimization problem over a class of potential ITRs. However, this formulation
does not directly allow for shared decision making wherein patient preferences are inte-
grated into the decision process (Barry and Edgman-Levitan 2012, Drake et al. 2010);
on the other hand, direct preference elicitation in which the patient chooses parameters
indexing a composite outcome is not feasible unless patients have undergone specialized
training (Brennan 1998, Braziunas 2006, Lizotte et al. 2012a). Thus, a common ap-
proach for preference elicitation is to administer a questionnaire populated with items
that are accessible (meaningful) to a patient in a domain context yet are informative
about a preferences in the outcome space. These questions may ask the patient to rank
or numerically score different health states and/or may ask about their attitudes or
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experiences with certain outcomes. We consider the simplest possible setting in which
the questionnaire comprises a series of binary questions; we use item response theory
(Embretson and Reise 2013) to estimate a conditional distribution over preferences
given a patient’s answers to the items in the questionnaire. We use this conditional
distribution to derive a preference-sensitive optimal ITR for each patient.
There is a vast literature on estimation for optimal ITRs assuming a single scalar
outcome. Estimators are typically broadly categorized as regression-based (Murphy
2005b, Henderson et al. 2010, Zhao et al. 2011, Qian and Murphy 2011, Goldberg
and Kosorok 2012, Moodie et al. 2012; 2014, Tian et al. 2014, Laber et al. 2014a) or
policy-search-based (Orellana et al. 2010, Zhang et al. 2012a, Zhao et al. 2012, Zhang
et al. 2012b; 2013, Zhao et al. 2014; 2015, Laber and Zhao 2015), though this division
is somewhat superficial (Taylor et al. 2015). The estimators referenced above assume
that a single outcome has be pre-specified and that this outcome faithfully represents
the preferences of all patients in the population of interest.
The literature that does not assume a fixed and known composite outcome is
scarce and none addresses patient-specific preferences directly through elicitation. There
are three primary approaches to estimation of optimal ITRs with multiple outcomes:
(i) set-valued treatment regimes; (ii) inverse-preference elicitation; and (iii) constrained
estimation. Set-valued treatment regimes (Laber et al. 2014b, Lizotte and Laber 2016)
map current patient information to a subset of possible treatment options that are
not estimated to be uniformly worse across all outcomes; the expectation is that a
single treatment will be selected from the recommended set using patient preferences
and clinical judgment (no guidance is provided on how this will be done). Thus, set-
valued treatment regimes incorporate patient preferences through selection from the
recommended subset but do not directly elicit preferences. Inverse-preference elicita-
tion (Lizotte et al. 2012a) attempts to communicate to a patient the implicit composite
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outcomes that would be consistent with each possible treatment choice, e.g., choosing
treatment 1 over treatment −1 corresponds to valuing side-effect burden at least three
times as much as efficacy. Application of inverse preference elicitation requires the
patient to interpret convex combinations of outcomes which may be difficult without
specialized training. Another approach to estimation of optimal ITRs with multiple
outcomes is to maximize the expectation of one outcome subject to constraints on a
functional of the distribution of the the remaining outcomes (Linn et al. 2016). This ap-
proach assumes that a single (unknown) composite outcome reflects patient preferences
across the entire population.
The proposed methodology incorporates patient preferences into treatment se-
lection in a way that is mathematically rigorous yet does not require the patient to
undergo specialized training or understand complex quantitative concepts. This has at
least two important clinical impacts: (i) it facilitates ‘patient-centered care’ in which
patients play a key role is decision making and the evaluation of their own health
outcomes; and (ii) it offers a principled means for matching patient preferences to an
optimal treatment based on potentially complex outcome profiles. While many clini-
cal and intervention scientists already seek to implement patient-centered care and to
personalize treatment decisions based on patient preferences, it is recognized that the
rapid introduction of new therapies and a high-degree of patient preference heterogene-
ity makes this a difficult task to perform using expert judgement alone (Smoller and
Nierenberg 1999, Basu and Meltzer 2007, Frank and Zeckhauser 2007, Hodgkin et al.
2012, Huskamp et al. 2013). The proposed methodology can be viewed as a tool for
clinical decision support in the context of patient-centered care.
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3.2 Optimal ITRs with Heterogeneous Patient Preferences
3.2.1 Setup and Notation
We assume that the observed data, {(W i,X i,Ai, Yi, Zi)}ni=1, comprises n inde-
pendent and identically distributed tuples (W ,X,A, Y,Z), one per subject, where:
W ∈ {0,1}p denotes answers to items in a preference questionnaire; X ∈ Rm denotes
pre-treatment patient covariates; A ∈ {−1,1} denotes the assigned treatment; Y,Z ∈ R
denote outcomes of interest, coded so that higher values are better. In the context of
our application to schizophrenia: W denotes subject’s responses to a subset of ques-
tions on the Hogan Drug Attitude Inventory (Hogan et al. 1983); X denotes patient
demographics, measures of symptom severity, and the presence/absence of comorbidi-
ties (see Section 3.4 for a complete description); A denotes perphenazine or atyptical
antipsychotic medication; Y denotes efficacy measured in terms of the Positive and
Negative Syndromes Scale (PANSS); and Z denotes a measure of side-effect severity.
In this context, an ITR, pi ∶ domW × domX → domA, is a map from answers on a
completed questionnaire and patient covariates to a recommended treatment; under pi a
patient with responsesW =w and covariatesX = x would be recommended treatment
pi(w,x).
To define an optimal ITR, we assume that each individual in the population
possesses a latent preference, denoted E ∈ R, which indexes a utility function, U(y, z; e),
that induces a total ordering on domY × domZ so that a patient with preference
E = e would prefer outcomes (y, z) to (y′, z′) if U(y, z; e) ≥ U(y′, z′; e). Let Y ∗(a) and
Z∗(a) denote the potential outcomes under treatments a ∈ {−1,1} (Rubin 1978) so that
U {Y ∗(a), Z∗(a);E} is the potential utility function under treatment a. For any ITR,
pi, define the potential utility as VU(pi) = E [∑a∈{−1,1}U {Y ∗(a), Z∗(a);E}1pi(W ,X)=a].
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The optimal regime, pioptU , satisfies VU (pioptU ) ≥ VU (pi) for all ITRs pi.
We assume a utility of the form U(y, z; e) = Φ(e)y + {1 −Φ(e)} z where Φ(⋅)
denotes the cumulative distribution function of a standard normal random variable.
The next result shows that this assumption incurs only a small loss of generality. Define
RZ(w,x) = E{Z∗(1)∣W =w,X = x} −E{Z∗(−1)∣W =w,X = x} ,
RY (w,x) = E{Y ∗(1)∣W =w,X = x} −E{Y ∗(−1)∣W =w,X = x} ,
RU(w,x) = E [U {Y ∗(1), Z∗(1);E} ∣W =w,X = x]
−E [U {Y ∗(−1), Z∗(−1);E} ∣W =w,X = x] ,
we assume that the foregoing quantities are well-defined for all w and x. It can be
shown that pioptU (w,x) = sign{RU(w,x)} (Qian and Murphy 2011). .
Lemma 3.2.1. Assume that max{RU(w,x)RZ(w,x), RU(w,x)RY (w,x)} > 0 for
all x, w. Then, there exists a real-valued random variable, E′, such that: (i) E′ ⊥
A,{{Z∗(a), Y ∗(a)} ∶ a ∈ {−1,1}}∣X,W ; and (ii) the ITR
pioptCVX(x,w) = arg max
a∈{−1,1}E [Φ(E′)Y ∗(a) + {1 −Φ(E′)}Z∗(a)∣X = x,W =w]
satisfies VU(pioptCVX) = VU(pioptU ).
Proof. Define ξ(w,x) = ∣RZ(w,x)/RY (w,x)∣sign{(RU (w,x)RZ(w,x)} if both RZ(w,x)
and RY (w,x) are nonzero, and ξ(w,x) = 1 otherwise. Set
E′ = E′(W ,X) = Φ−1[ξ(W ,X)/ {1 + ξ(W ,X)} ]+sign{RU(W ,X)RY (W ,X)} . Thus,
given W = w and X = x, E′ = e′ is completely determined so that, pioptCVX(w,x) =
sign [Φ(e′)RY (w,x) + {1 −Φ(e′)}RZ(w,x)] which can be seen (after some algebra) to
equal pioptU (w,x) = sign{RU(w,x)}. ∎
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The preceding result states that a latent preference model that assumes a convex
utility function is sufficiently expressive provided that the sign of RU(w,x) matches
the sign of RY (w,x) or RZ(w,x); i.e., for any w,x the optimal policy under the
unknown utility would recommend a treatment that is satisfactory to patients who
care only about outcome Y or care only about outcome Z. Note that violation of this
assumption would imply that there exists a pair (x,w) such that under U a patient
would prefer a treatment that was worse on both outcomes which is unrealistic in many
settings.
3.2.2 Estimating an Optimal ITR
To construct an estimator of piopt we first express it in terms of the under-
lying generative model. We assume: (C1) consistency, (Y,Z) = {Y ∗(A), Z∗(A)};
(C2) positivity, there exists  > 0 so that P (A = a∣X,W ) ≥  for each a, with
probability one; (C3) ignorability, [{Y ∗(a), Z∗(a)} ∶ a ∈ {−1,1}] ⊥ A∣X,W ; and (C4)(A,Y,Z) ⊥ E∣X,W . The first three assumptions are standard (Robins et al. 2000,
Zhang et al. 2012b) whereas (C4) can be satisfied provided the conditions of Lemma
(3.2.1) hold. Under (C1)-(C3) it can be shown (Schulte et al. 2014) that piopt(x,w) =
arg maxa∈{−1,1}E[Φ(E)Y + {1 −Φ(E)}Z ∣X = x,W =w,A = a] which, under (C4), can
be written as
piopt(x,w) = arg max
a∈{−1,1} [E{Φ(E)∣X = x,W =w}E (Y ∣X = x,W =w,A = a)
+ [1 −E{Φ(E)∣X = x,W =w}]E (Z ∣X = x,W =w,A = a) ].
The foregoing expression suggests the following approach for estimating piopt: (i) con-
struct estimators, say Q̂Y,n(x,w, a) and Q̂Z,n(x,w, a), of QY,n(x,w,a) = E(Y ∣X =
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x,W = w,A = a) and QZ(x,w, a) = E(Z ∣X = x,W = w,A = a); (ii) postulate
a latent preference model linking the unobservable preference E with covariates X
and preference questionnaire items W and use this postulated model to construct an
estimator, say µ̂E,n(x,w) of µ(x,w) = E{Φ(E) ∣X = x,W =w}; and (iii) compute
p̂in(x,w) = arg maxa∈{−1,1} [µ̂E,n(x,w)Q̂Y,n(x,w, a) + {1 − µ̂E,n(x,w)} Q̂Z,n(x,w, a)].
Below we describe an instantiate of this approach that appears to work well in practice
and possesses a number of desirable theoretical properties.
To construct estimators of QY (x,w, a) and QZ(x,w, a) we postulate linear work-
ing models of the form QY (x,w, a;ψY ) = x⊺Y,0ψY,0 + w⊺Y,1ψY,1 + ax⊺Y,1ψY,2 + aw⊺Y,1ψY,3
and QZ(x,w, a;ψZ) = x⊺Z,0ψZ,0 +w⊺Z,0ψZ,1 + ax⊺Z,1ψZ,2 + aw⊺Z,1ψZ,3, where x`,j and w`,j
for ` = Y,Z and j = 0,1 are known feature vectors constructed from x and w and
ψW , ψY are unknown parameter vectors. Note that we assume this linear form for
simplicity and in practice this form of the working model should be in line with cur-
rent literature and previous analyses. Let Pn denote the empirical measure and define
ψ̂Y,n = arg minψY Pn {Y −QY (X,W ,A;ψY )}2 and
ψ̂Z,n = arg minψZ Pn {Z −QZ(X,W ,A;ψZ)}2. Subsequently, we construct estimators
QY (x,w, a; ψ̂Y ) and QZ(x,w, a; ψ̂Z) of QY (x,w, a) and QZ(x,w, a).
To develop our latent preference model, we assume (C5) that E ⊥ X ∣W . This
assumption simplifies our development and is justified in our application whereX does
not contain information thought to be informative about patient preferences beyond
W ; however, this assumption is not necessary (De Ayala 2013). We assume that latent
patient preferences are connected to items on the questionnaire through a Rasch model
(Rasch 1961; 1980) of the form logit{P (Wj = 1∣E = e)} = β0,j +β1,je, j = 1, . . . , p which
is indexed by β = (β0,1, β1,1, . . . , β0,p, β1,p). Let β∗ denote the true parameter value; we
use the EM algorithm to construct an estimator, β̂n, of β∗ (Rizopoulos 2006).
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Given estimator β̂n and a postulated marginal distribution, say pe, for the la-
tent preferences, the conditional distribution of E given W = w is proportional to
p(w∣e)ph(e) which can be approximated using Metropolis Hastings. Because the con-
ditional distribution of E is only used to construct an estimator of
µ(x,w) = E{Φ(E)∣X = x,W =w} and because we assume that µ(x,w) does not
depend on x, it is computationally less burdensome to apply a method of moments
type estimator. Let ên(w) denote the solution to ∑pj=1 β̂n,1,jexpit (β̂n,j,0 + β̂n,1,je) =∑pj=1 β̂n,1,jwj, where expit(u) = exp(u)/ {1 + exp(u)}. Subsequently, let µ̂E,n(x,w) =
Φ{ên(w)} denote our estimator of µ(w,x). Results provided in Appendix A.1 and A.2
of the Supplemental Material show that this estimator provides qualitatively similar
results as Metropolis Hastings while being significantly less computationally intensive.
Theoretical results
Let e∗(w) denote the solution to ∑pj=1 β∗1,jexpit(β∗j,0 + β∗j,1e) = ∑pj=1 β∗j,1wj. We
make the following assumptions
(A1) The number of items satisfies 3 ≤ pn = o(en).
(A2) The estimator ên(w) converges in probability to e∗(w), pointwise for all w.
(A3) The estimators Q̂Y,n(x,w, a) and Q̂Z,n(x,w, a) converge in probability to
QY,n(x,w,a) and QZ,n(x,w,a), pointwise for each x and w.
The preceding assumptions are rather mild: (A1) can be expected to hold in many
applications as it is common to have p ≪ n; (A2) holds under standard regularlity
conditions for methods of moments estimators; and (A3) holds under standard linear
modeling assumptions.
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The first result establishes consistency of the proposed estimator for the optimal
regimen as the sample size diverges but the number of items remains fixed.
Theorem 3.2.2. Assume (A1)-(A3) and let the number of items, pn = p, be fixed.
Then VU(piopt) − VU(p̂in) converges to zero in probability as n→∞.
The preceding result is relevant when the number of items is small relative to the
number of enrolled subjects, e.g., in the illustrative example presented in Section 3.4
there are p = 10 items and n = 957 subjects. However, the next result shows that if the
number of items is allowed to diverge with the sample size then the estimated optimal
regime performs as well as an oracle with access to each patient’s individual preference.
Theorem 3.2.3. Assume (A1)-(A3) and suppose pn →∞ as n→∞.
Define pioracle(x, e) = arg maxaE(U ∣X = x,E = e,A = a) denote the optimal policy if pa-
tient preferences were known. Then VU(p̂in)−VU(pioracle) converges to zero in probability
as n→∞.
The proof of the preceding result involves, as an intermediate step, proving consis-
tency of the Rasch model for individual patient preferences when the number of items
is nearly exponential in the number of patients. To our knowledge, this is new result
in item response theory that may be of independent interest.
3.3 Simulation Study
In this section we examine the finite sample performance of the proposed estima-
tion method in terms of the average value obtained. Additional simulations comparing
the method of moments estimator with Metropolis Hastings are provided in Appendix
A.2 of the Supplemental Material.
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3.3.1 Data Generating Model
We consider the following class of generative models. Latent preferences are
drawn as i.i.d. so that E ∼ Normal(0,1). Responses to items are drawn i.i.d. so that
Wj ∼ Bernoulli{expit(β0,j +β1,jE)}; the true beta parameters are chosen to ensure that
when Ên(W ) was regressed onW using a probit regression model, the Nagelkerke’s R2
was equal to 0.5. The treatment, covariates, and outcome data were drawn i.i.d. so that:
A ∼ Unif{−1,1}, X ∼ N5(0, I5), Y =X⊺ψ00 +AX⊺ψ01 +  and Z =X⊺ψ10 +AX⊺ψ11 + δ
where , δ ∼ N(0,1), ψ00 = (2.5, .2, .25,−.7,−2.5,2.4), ψ01 = (1.7,−2.3,4.5,6,−7.3,−1.6),
ψ10 = t + q∗ψ00 and ψ11 = t + q∗ψ01. We set q = −2 and t = 3 so that the outcomes favor
different treatments about 85% of the time; other settings provide qualitatively similar
results and are provided in the Supplemental Material.
3.3.2 Simulation Results
The simulations were each repeated s = 500 times for all combinations of n =
25,50,100,200 and p = 5,10,20,50. Let QU(x,w, a) = E (U ∣X = x,W =w,A = a) and
Q̂U(x,w, a) = µ̂E,n(x,w)Q̂Y,n(x,w, a) + {1 − µ̂E,n(x,w)} Q̂Z,n(x,w, a) to be the pro-
posed estimator of QU(x,w, a). In our first simulation experiment we compute the
average squared difference between the estimated value function and the true value
function of the optimal regime. The results are displayed in Figure 3.1. When we
compare the average squared difference between V̂U(p̂in) = Pn maxa Q̂U(X,W , a) and
VU(piopt), it can be seen that the quality of the estimated value improves as either n
or p increases. As expected, we can see from the averaged squared distance between
V̂Y (p̂in) = Pn maxa Q̂Y (X,W , a) and VY (piopt) that the quality of the approximation
improves as n increases but is insensitive to changes in p. We see an analogous pattern
in the average difference between V̂Z(p̂in) and VZ(piopt).
61
Figure 3.1: Averaged squared difference: V̂U (p̂in) , V̂Y (p̂in) and V̂Z(p̂in)
a : V̂U(p̂in) and VU(piopt) b : V̂Y (p̂in) and VY (piopt) c : V̂Z(p̂in) and VZ(piopt)
We also compared p̂in with piopt and pioracle in terms of treatment recommendations.
Figure 3.2 shows the average percentage of disagreement of p̂in with piopt and pioracle.
It can be see that the level of agreement is generally high and, as anticipated by the
theoretical results in the preceding section, the agreement improves as n and p increase.
Figure 3.2: Average percent disagreement: p̂in, piopt and pioracle
a : Average disagreement between p̂in and piopt b : Average disagreement between p̂in and pioracle
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3.4 Case Study
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophre-
nia trial was designed to compare new antipsychotic drugs to conventional ones in
a randomized, controlled, double blinded, multi-phase trial (Lieberman et al. 2005,
Stroup et al. 2003, Davis et al. 2003; 2011). The trial was intended for patients who
were already being treated for schizophrenia but who might benefit from a medicinal
change. The patients not only received antipsychotic treatments, but were also of-
fered psychosocial treatment with their families. In the first phase of the trial patients
were randomized to one of 5 medications: 4 of which were atypical antipsychotics
(olanzapine, quetiapine, risperidone and ziprasidone) and one conventional antipsy-
chotic (perphenazine). The primary study analysis (Lieberman et al. 2005) compared
all treatments individually, and identified substantial variability amongst the atypi-
cals. However, for the purposes of this illustration, we dichotomize treatment into
two groups: atypical antipsychotics and perphenazine. Patients who discontinued their
treatment would move to phase 2 and would be randomized to another treatment ac-
cording to the protocol. The structure of the first phase of this trial makes it an ideal
application for the method presented in this paper. At baseline, patients answered a
10 question, binary-response assessment, which we use as a measure of the patient’s
preference across two outcomes: (i) efficacy measured using the Positive and Negative
Syndromes Scale (PANSS) (Kay et al. 1987); and (ii) side effect burden measured as the
sum of side effect and adverse event indicators. Detailed descriptions of these outcomes
are provided in Appendix A.3 of the Supplemental Material. Outcomes were measured
at the end of the first phase, or throughout the phase for adverse events. The end of the
first phase occurred when the patient underwent a treatment change (at the discretion
of the patient and clinician) or 18 months, whichever came first.
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The patient preference information was collected using a 10 question Drug Atti-
tude Inventory (Hogan et al. 1983) assessment that each patient answered at the base-
line. We opted to exclude one question (“I take medications of my own free choice")
because it cannot be interpreted as a trade-off between two outcomes of interest. The
remaining 9 questions are as follows and were coded so that (1) favors efficacy and (0)
favors side effect burden.
1. “For me, the good things about medication outweigh the bad" Yes (1) No (0)
2. “I feel weird, like a ‘zombie’, on medication" Yes (0) No (1)
3. “Medications make me feel more relaxed" Yes (1) No (0)
4. “Medications make me feel tired and sluggish" Yes (0) No (1)
5. “I take medications only when I’m sick" Yes (0) No (1)
6. “I feel more normal on medication" Yes (1) No (0)
7. “It is unnatural for my mind and body to be controlled by medications" Yes (0)
No (1)
8. “My thoughts are clearer on medication" Yes (1) No (0)
9. “By staying on medications I can prevent being sick" Yes (1) No (0)
We selected tailoring covariates based on clinical expertise and prior analyses
(Shortreed and Moodie 2012, Shortreed et al. 2014). The variables included in our
analysis are gender, age, race (white, black, other), BMI, diastolic blood pressure, sys-
tolic blood pressure, baseline clinical severity of schizophrenia, age at first antipsychotic
medication, and any antipsychotic medication they were taking at the baseline (olan-
zapine, quetiapine, risperidone, ziprasidone, perphenazine, haldol, or any long-term
injectable antipsychotic).
The estimated optimal treatment allocations for each treatment by outcome is
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displayed in Table 3.1. While efficacy appears to favor atypical antipsychotics, side ef-
fect burden tends to favor perphenazine. As expected, the composite outcome occupies
a middle ground between the two marginal outcomes; the optimal treatment for the
composite outcome and efficacy are the same 92% of the time, the optimal treatment
for the composite outcome and side effect burden are the same 64% of the time, and
the optimal treatment for efficacy and side effect burden are the same 56% of the time.
Another view of these data is presented in Table 3.2 which shows the fraction of overlap
between the estimated optimal regime using the proposed estimator and the optimal
regime based only on efficacy or side effect burden.
Table 3.1: Treatment recommendations
Perphenazine Atypical Antipsychotics
p̂iY : Efficacy 36% 64%
p̂iZ : Side Effect Burden 67% 33%
p̂in: Φ(E)Y + {1 −Φ(E)}Z 41% 59%
Table 3.2: Percent of agreement in treatment recommendations
p̂iY : Efficacy p̂iZ : Side Effect Burden
Both recommend perphenazine 35% 36%
Only p̂in recommends perphenazine 6% 5%
Only p̂in recommends atypical antipsychotic 2% 31%
Both recommend atypical antipsychotic 57% 28%
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3.5 Discussion
Clinical and intervention scientists must often balance multiple, possibly compet-
ing outcomes when designing a personalized treatment plan for a patient. We combined
a latent trait model with Q-learning to incorporate individual patient preferences into
an evidence-based treatment plan formalized as a treatment regime. The proposed
estimator is consistent for the optimal regime and possesses an oracle property if the
number of items on the preference questionnaire is allowed to diverge with sample size;
incidentally, to establish these results we developed new theory for Rasch model that
may be of interest beyond the application we consider here. We view the proposed
methodology as an important first step toward mathematical formalizations of shared
decision making in the context of precision medicine.
There are number of interesting and important extensions of the proposed method-
ology. The extension to settings with multiple treatment periods is of particular inter-
est. This extension is challenging as a patient’s preferences may change over time in
response to treatment received and interim outcomes experienced, e.g., a patient who
experiences severe side effects may develop a strong aversion to them in the future.
Furthermore, in applications where interventions are delivered on a fine time scale,
e.g., mobile-health, one must judiciously choose the timetable for administering the
preference questionnaire to balance information gain with patient burden.
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CHAPTER 4: ESTIMATING DYNAMIC TREATMENT STRATEGIES
BY INTEGRATING PATIENT PREFERENCES
4.1 Introduction
The clinical treatment of patients with chronic disease is evolving every day.
Patient care now focuses on determining which treatment(s) should be administered,
who they should be administered to, and at which stage in the treatment plan they
should be administered (Collins and Varmus 2015). Individual characteristics such as
prognostic information, treatment history and familial data are taken into consideration
when estimating a time dependent set of treatment rules called dynamic treatment
regimes (DTRs). DTRs serve as a set of treatment decisions that evolve through time
determined by patient progress and prognostic variables with the goal of optimizing a
patient’s long term outcome (Collins et al. 2014). These rules take advantage of the
fact that treatments have different levels of efficacy in tandem with other treatments.
This ensures they identify which course of treatment is the best overall as opposed
to myopically determining which treatment is the best at each stage. The statistical
goal is to mathematically mimic how clinicians treat patients in practice (Collins et al.
2007). The type of data that is needed to estimate DTRs is most efficiently collected
from a sequential multiple assignment randomization trial. These trials specialize in
using a small sample size to efficiently collect information on multiple treatment paths
(Kidwell 2014). Therefore, it is often important to develop an accurate estimate of the
optimal treatment strategy that can accommodate a reduced sample size.
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These individual characteristics can also include patient preference information
regarding how to weigh the importance of two competing clinical outcomes (Edwards
and Elwyn 2009). There are multiple ways to collect preference information. Patients
can directly choose parameters that summarize their preferences. Unfortunately, this
often requires formal training, which is not feasible in most treatment settings (Brennan
1998, Braziunas 2006, Lizotte et al. 2012a). Alternatively, since this information is
considered unobservable, the patient can answer a series of questions on a questionnaire
and, from this, the patient’s preference can be estimated (Embretson and Reise 2013).
These questions can require a patient to choose from binary responses or rank a set of
ordered responses that correspond to one of the competing outcomes. While there is a
multitude of research on how to collect and even summarize latent patient information,
there has been little work on how to incorporate it when estimating DTRs.
The method presented here estimates optimal DTRs for competing outcomes,
such as efficiency versus toxicity, in line with the patient’s preferences concerning these
two outcomes. The idea is that one treatment may well favor one outcome and the
other treatment favor the other. It is important to determine how, when, and to
whom these should be allocated. The ideal situation is to accurately elicit patient
preferences and integrate them into a composite outcome that creates a linear trade off
between the two clinical outcomes. We chose to use an item response theory approach
to estimate a patient’s preferences by analyzing the set of dichotomous responses to
carefully constructed questions using a latent trait model (Rizopoulos 2006). The
optimal treatment rule is determined as that which provides the maximum expected
utility given the patient’s history, assuming that the best treatment is assigned at all
subsequent stages. The preference information is updated at each treatment stage
based on how their preferences have changed and their overall contentment with their
health status. Section 3 presented the basis for this work in the single stage scenario.
68
Our method extends that to the multiple stage scenario using a reinforcement learning
technique called Q-learning (Watkins and Dayan 1992). For the purposes of our work,
the method is only presented for the two-stage setting since it is mathematically trivial
to extend this to 3 or more decision stages. In a simulation study, the estimated optimal
dynamic treatment rule is compared with the true optimal dynamic treatment rule and
the optimal static treatment rule for varying sample sizes and number of questions in
the questionnaire. The static treatment rule assumes patient preferences do not change
over time and uses the preference information only collected at the baseline; otherwise,
the rest of the estimation procedure is the same. While this method has the desirable
asymptotic properties, it is also shown to be quite accurate with smaller sample sizes
and a reasonably sized preference questionnaire.
4.2 Estimating the Optimal DTR
4.2.1 Framework
Assume the observed data are
{(X1i ,W 1i ,A1i ,B1i , Y 1i , Z1i , . . . ,XTi ,W Ti ,ATi ,BTi , Y Ti , ZTi ,W T+1i )}ni=1
which comprise n iid trajectories of the form (X1,W 1,A1,B1, Y 1, Z1, . . . ,
XT ,W T ,AT ,BT , Y T , ZT ,W T+1). Then, X t ∈ Rm indicates the patient covariate in-
formation collected preceding assigning the treatment at time t; W t ∈ {0,1}p denotes
responses to the itemized questionnaire administered before assign the treatment at
time t; At ∈ At denotes the treatment assigned at time t; Y t ∈ R is the first out-
come measured after receiving treatment at time t; Zt ∈ R is the second outcome
measured after receiving treatment at time t. Bt ∈ {0,1} denotes an indicator that
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the patient is content with the outcome observed after receiving treatment at time t.
We include a measure of the patient’s contentment because it allows us to calibrate
how well the assigned treatment is aligning with the patient’s preferences and their
observed outcome. Let H t denote the patient’s history, or the information available
to the decision maker before treatment assignment at time t so that H1 = X1 and
H t = {H t−1,At−1,Bt−1, Y t−1, Zt−1,X t} for t = 2, . . . , T .
In the context treatment of schizophrenia, our motivating example, X denotes
patient prognostic information such as demographic variables; W measures subject’s
responses on a set of questions concerning the two competing outcomes (severity of
psychotic symptoms and aggregate side effect burden) ; A denotes two treatments, one
of which is associated with higher alleviation of depression severity but higher side
effects and the other is associated with lower alleviation of depression severity but also
lower side effects; B indicates if the patient is satisfied with their overall wellbeing; Y
denotes the severity of the depression; and Z denotes a measure of aggregate side-effect
severity.
We define the set of dynamic treatment rules as pi = (pi1, . . . , piT ). At stage t, the
function pit ∶ domW t×domH t → domAt is a map from the patient’s itemized response
and history to the recommended treatment rule. This means that for pit a patient
with questionnaire responses W t = wt and history H t = ht would be recommended
treatment pit(wt,ht). We assume that for each time, t, a patient’s preferences are
summarized by Et ∈ R. Et denotes the patients value of outcomes Y t compared to Zt
and are assumed to change across time. The utility function that represents a trade
off between the outcomes in line with the patient’s preferences is u(yt, zt, et). Then,
a patient with preference Et = et would prefer the outcome set (yt, zt) over (y˜t, z˜t)
if u(yt, zt, et) > u(y˜t, z˜t, e˜t). Let V (pit) = Epi[u(Y t, Zt,Et)] denote the value function
which is the expected utility under treatment pit. Then, the treatment rule pit,opt is
70
said to be optimal if V (pit,opt) ≥ V (pit) ∀ pit. The goal is to estimate pit,opt for all
t. Let us denote Y t,∗(at) and Zt,∗(at) as the potential outcomes for Y t, Zt at stage
t under treatment at ∈ {−1,1} (Rubin 1978). Then denote the utility function as
u(Y t,∗(at), Zt,∗(at),Et,∗) and the value function as
Vu(pit) = E⎡⎢⎢⎢⎢⎣ ∑at∈{−1,1}u{Y t,∗(at), Zt,∗(at),Et}1{pi (W t,H t) = at}
⎤⎥⎥⎥⎥⎦ .
The optimal treatment at time t, pit,optu , is that which satisfies Vu (pit,optu ) ≥ Vu (pitu) for
all pitu.
We propose the following additive parametric model for the utility function,
u(y, z, e) = ΣTt=1u(yt, zt, et;ρt), which is indexed by an unknown parameter ρt ∈ Rd.
The optimal treatment rule can be characterized in terms of the underlying generative
model. For any ρt, define
QT (hT , aT ) ≜ E{ΣTt=1u(Y t, Zt,Et;ρt)∣HT = hT ,AT = aT}
as the Q-function for the last follow-up stage T . Then piT,opt(hT ) = argmaxaTQT (hT , aT ).
The backwards recursive Q-functions for T = T − 1, T − 2, . . . ,1 are defined as
Qt(ht, at) ≜ E{maxat+1Qt+1(ht+1, at+1))∣H t = ht,At = at}
where pit,opt(ht) = argmaxatQt(ht, at). Provided Q̂t is an estimator of Qt, then the
optimal treatment rule for t = 1, . . . , T is p̂itn(ht) = argmaxatQ̂tn(ht, at).
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4.2.2 Methodology
We assume a linear trade off between the outcomes because it is reasonable to
assume a patient would prefer one outcome to the other by a certain magnitude. Hence,
we set the utility function to be u(Y t, Zt,Et;ρt) = Φ(Et)Y t + (1 −Φ(Et))Ztρt so that
the weight is a function of the patient preferences. Note that Φ(⋅) is the cumulative
distribution function of the standard normal distribution and is used as a normalizing
factor to ensure Φ(Et) ∈ [0,1]. In this function, ρt represents either a penalty or reward
that is commensurate with contentment. ρt can take any value greater than zero. By
increasing or decreasing the magnitude of the second outcome’s contribution to the
utility function, we can better control for the patient’s feelings about the results of
their previous treatment. To construct our estimator, we make the following assump-
tions: (C1) consistency, (Y t, Zt) = {Y t,∗(At), Zt,∗(At)}, which implies the individuals
observed outcome is the potential outcomes associated with the observed treatment;
(C2) positivity, P (A = a∣X,W ) ≥  for some  > 0 and each a , with probability one,
which implies that there is a positive probability of receiving all possible treatments;
(C3) ignorability,[{Y t,∗(at), Zt,∗(at)} ∶ at ∈ {−1,1}] ⊥ At∣H t,W t; and (C4) (At, Y t, Zt) ⊥ Et∣H t,W t,
which reasonably implies that the patient’s preferences are independent of the the as-
signed treatment and the outcomes. The first three assumptions are standard (Robins
et al. 2000, Zhang et al. 2012b). (C4) can be satisfied as shown in section 3.2.2. Under
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these assumptions the optimal policy can be written as
pit,opt(ht,wt) =
arg max
atin{−1,1} [E{Φ(Et)∣H t = ht,W t =wt}E (Y t∣H t = ht,W t =wt,At = at)
+ [1 −E{Φ(Et)∣H t = ht,W t =wt}]E (Zt∣H t = ht,W t =wt,At = at) ρ̂t].
The following describes the approach we took to estimating the sequence of dy-
namic treatment rules piopt = (pi1,opt, . . . , piT,opt):
1. Develop the posterior distribution model of the latent preference information,
Et, given the patient’s history, H t, contentment of outcomes after treatment,
Bt, and responses to the preference questionnaire, W t, for all t. Use this pos-
terior model to construct and estimate the patient’s estimated conditional la-
tent preference at the final stage, t = T , as η̂ET ,n(hT ,wT ) where η(hT ,wT ) =
E{Φ(ET ) ∣HT = hT ,W T =wT}.
2. Construct estimators of the conditional distribution of each of the outcomes
given the patient’s history, HT , responses to the questionnaire, W T , and treat-
ment, AT , where QY T ,n(hT ,wT , aT ) = E(Y T ∣HT = hT ,W T = wT ,AT = aT ) and
QZT (hT ,wT , aT ) = E(ZT ∣HT = hT ,W T = wT ,AT = aT ). Note that we assume
a linear form of the conditional distribution for simplicity, but this can easily be
generalized to any other form in practice.
3. Define
Q̂Tn(hT ,wT , aT ) = η̂ET ,n(hT ,wT )Q̂Y T ,n(hT ,wT , aT )
+ {1 − η̂ET ,n(hT ,wT )}Q̂ZT ,n(hT ,wT , aT )ρT
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and p̂iT,opt = arg maxaT ∈{−1,1} Q̂Tn(hT ,wT , aT ).
4. Using Q-learning, repeat steps (i)-(iii) for t = T −1, T −2, . . . ,1 with the exception
that the Q-function is defined as follows:
Q̂t,∗n (ht,wt, at) = η̂Et,n(ht,wt)Q̂Y t,n(ht,wt, at)
+ {1 − η̂Et,n(ht,wt)}Q̂Zt,n(ht,wt, at)ρt
Q̂tn(ht,wt, at) = Q̂t,∗n (ht,wt, at) + Q̂t+1n (ht+1,wt+1, at+1 = p̂it+1,opt)
We assume the preference and utility are related to the observed data through three
models, the item response model, the contentment model and the preference evolution
model as follows:
• (Item Response Model) logitP (W tj = 1∣H t = ht,Et = et) = γtj,0 + γtj,1et
• (Contentment Model) logitP (Bt = 1∣H t = ht,At = at, Y t = yt, Zt = zt,Et+1 =
et+1) = ζ0 + ζ1u(yt, zt, et+1;ρt)
• (Preference Evolution Model) E1 ∼ N(0,1); Et+1 = µ(yt, zt; τ) + τ1 + et + τ2atet +
t, t ∼ N(0,1)
The form of µ is assumed to be known as µ(Y t, Zt; τ) = τ00 + τ01yt + τ02zt. No-
tice that the contentment depends on the future preference information, et+1. This
is because at the time Bt is collected the patient is describing their contentment
with the outcomes (Y t, Zt) in terms of their current preferences and not the one
that preceded the assignment of At. The estimates of β are found from the latent
trait model; estimates of τ t are obtained using the following linear regression model:
E(Et) = τ t0 + τ t1yt−1 + τ t2zt−1 + τ t3et−1 + τ t4at−1et−1; estimates of ζt, ρt are obtained using
logistic regression of the following model: logitP (Bt = 1∣H t = ht,At = at, Y t = yt, Zt =
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zt,Et+1 = et+1) = ζt1+ζt2[Φ(et+1)yt+{1−Φ(et+1)}ztρt]. Given these estimated parameters,
the posterior distribution of the latent preference is defined as
P (Et∣H t)∝ P (Bt−1∣Et, Y t−1, Zt−1)P (W t∣Et)P (Et∣Y t−1, Zt−1).
From this, a Metropolis Hastings algorithm can be used to estimate the posterior mean
where the estimator of the trade-off weight is η̂ET ,n(hT ,wT ) = Φ(êt).
We define linear working models of the form QY T (hT ,wT , aT ;γY ) = hTγ0,0 +
aThTγ0,1 and QZT (hT ,wT , aT ;γZ) = hTγ1,0 + aThTγ1,1 and obtain parameter esti-
mates of γ̂0,0, γ̂0,1, γ̂1,0, γ̂1,1 using simple linear regression. Then, Q̂Y T ,n(hT ,wT , aT )
and Q̂ZT ,n(hT ,wT , aT ) be the fitted estimators such that
Q̂Tn(hT ,wT , aT ) = Φ(êT )Q̂Y T ,n(hT ,wT , aT ) + [1 −Φ(êT )]Q̂ZT ,n(hT ,wT , aT )ρ̂T .
For t < T the structure of the linear working models for Q̂Y t,n, Q̂Zt,n is the same. The Q-
function for the composite outcome is similar such that Q̂tn(ht,wt, at) = Q̂t,∗n (ht,wt, at)+
Q̂t+1n (ht+1,wt+1, at+1 = p̂it+1,opt).
4.3 Simulation Study
4.3.1 Data Generating Model
For the simulation study, we generated the data as to mimic what would be
collected in a clinical trial. Each treatment, Ati, is randomly generated as 1 or -1. The
covariates, X, are assumed to be observed at all T stages and are correlated between
stages for each subject. λ and κ are randomly chosen to be used for all simulations.
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The covariance of X i is defined using the following ARMA(1,1) structure:
ΣXi =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 λ λ∗κ λ∗κ3 . . . λ∗κt−1
λ 1 λ λ∗κ2 . . . λ∗κt−2⋮ ⋱ ⋮
λ∗κt−1 λ∗κt−2 λ∗κt−3 λ . . . 1
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
For each of the m=5 covariates, xi,t = {xi,1, xi,2, . . . , xi,T} ∼ MVN(0¯T ,ΣXi) At stage
t > 1, each of the covariates experienced a positive or negative “drift" depending on if
they received treatment A = 1 or A = −1 at stage 1. The purpose of this drift is to mimic
the effect of the treatment on each of the covariates at the subsequent stage. At the first
stage, we let 1i ∼ N(0,1) and δ1i ∼ N(0,1) be random noise, where 1 = {1i , . . . , 1n} and
δ1 = {δ1i , . . . , δ1n}. Let Y 1 and Z1 be the outcomes at the first stage. Then, Y 1 =X1γ0,0+
A1X1γ0,1+1 and Z1 =X1γ1,0+A1X1γ1,1+δ1. At the second stage, we let 2i ∼ N(0,1)
and δ2i ∼ N(0,1) be random noise, where 2 = {2i , . . . , 2n} and δ2 = {δ2i , . . . , δ2n}. Let
Y 2 and Z2 be the outcomes at the second stage and G1 = (X1,A1, Y 1, Z1). Then,
Y 2 = X2γ0,0 + A2X2γ0,1 + G1γ0,2 + 2 and Z1 = X1γ1,0 + A2X2γ1,1 + G1γ1,2 + δ2. For
the latent preference information, E, we assume E1 ∼ N(0,1) at the first stage and
Et = τ t1Y t−1+τ t2Zt−1+τ t3Et−1+τ t4At−1Et−1+ for all subsequent stages. The responses the
the itemized questionnaire,W , are assumed to follow a binomial distribution such that
W ti,j ∣Eti ∼ Bernoulli(expit{β0,j,k + β1,j,kEti}). To generate the measure of contentment
after each stage, B, let ρt > 0, ζt1, ζt2 ∈ R and ut = Φ(Et)Y t−1+(1−Φ(Et))Zt−1ρt. We also
assume Bt follow a Bernoulli distribution such that Bt ∼ Bernoulli(expit{ζt1 + ζt2ut}).
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4.3.2 Simulation Results
For all combinations of n = 25,50,100,200 and p = 5,10,20,50, the simulations
were repeated s = 500 times. In all instances, we assume there are only t = 2 treatment
stages, but the steps of Q learning can easily be extended to more than 2 stages.
Figure 4.1 shows the percent of simulations the true and estimated dynamic treat-
ment rule differ at the second stage and the percent of simulations the estimated dy-
namic and static treatment rules differ for at the second stage. When looking at the
true versus estimated dynamic treatment rule heatmap (on the left), we see that for
stage 2 the method becomes more accurate as n and p increase. While there is still in-
creased accuracy, the magnitude of the increase decreases from 100 observations to 150
observations, which may suggest it is sufficient to only include 100 observations. We
also see a small increase in the magnitude of the estimator’s accuracy between 20 items
and 30 items, which may also suggest that it is sufficient to only include 20 items in
the preference questionnaire. Turning to the estimated optimal dynamic versus static
treatment rule (on the right), there appears to be more disagreement as p increases
which implies that as we increase the number of items in the questionnaire the static
estimator and the dynamic estimator are favoring different outcomes. As expected,
there is not much evidence of a trend across n. This is because the difference between
the dynamic and static estimator is the estimated latent preference information, Φ(ê),
which is dependent on p, not n.
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Figure 4.1: Average percent disagreement: p̂i2D, pi
2
T and p̂i
2
S
a : Average disagreement between p̂i2D and pi
2
T b : Average disagreement between p̂i
2
D and p̂i
2
S
Figure 4.2 shows the percent of simulations the true and estimated dynamic treat-
ment rule differ at the first stage and the percent of simulations the estimated optimal
dynamic and static treatment rules differ for at the first stage. In looking at the true
versus estimated optimal treatment rule heatmap (on the left), we see that at stage 1,
the method becomes more accurate as n and p increase. We note that when n = 150 and
p = 30 there is a slight increase in disagreement, which may imply that that many ob-
servations combined with items does not provide much additional information. We also
notice that there is more disagreement in stage 1 than stage 2, which may be attributed
to the mechanisms of Q-learning. This is because in all the steps where t < T , the Q
function incorporates the expected utility of using the optimal treatment at the future
stage, which introduces some variability. Turning to the estimated optimal dynamic
versus static treatment rule (on the right), there is substantially less disagreement at
stage 1 than at stage 2. This is likely because the estimated preference from stage 1 is
used for stage 2 in the static estimator. It appears there is slightly more disagreement
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between the dynamic and static rules for smaller sample sizes, but not much difference
across items.
Figure 4.2: Average percent disagreement: p̂i1D, pi
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4.4 Discussion
We have presented a new method to estimate optimal dynamic treatment plans
that consider patient preferences about a set of 2 competing outcomes. The pre-
specified utility function serves as the composite outcome and is a linear combination of
the preference information and the two competing outcomes. This new outcome is used
in Q-learning to estimate which treatment is optimal at each stage, assuming that the
best treatment is given at subsequent stages. In each stage, the Q-function estimates
the utility of each treatment given the patient’s personal and treatment history and
assigns the treatment that elicits the highest utility. The latent preference information
is estimated using an itemized questionnaire and whether the patient was content with
their status after receiving their previous treatment. This is done using item response
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theory, specifically the Rasch probability model, and utilizes a Metropolis Hastings
algorithm to estimate the conditional latent preference information. Under the given
assumptions, the method proves accurate, even for smaller sample sizes and a small
number of items on the questionnaire. This method provides a way for clinicians to
tailor the treatment regime to each patient based on their preferences as well as how
they are progressing at each point in time. It also takes the whole sequential treatment
plan into account as opposed to estimating the treatment at each stage on its own.
There are a handful of limitations to this work that can expanded upon in the
future to provide meaningful progress in the field of precision medicine. The composite
outcome is a linear function of the predicted outcomes and the latent preference esti-
mate. This could be improved upon by using a nonparametric or semi-parametric com-
posite outcome. We also only looked at two competing outcomes. It would strengthen
this line of work to be able to account for 3 or more competing outcomes. Balancing
3 outcomes requires a more developed form of the latent trait model for polytomous
data (that could be linear, or nonlinear, in form). It would also be extremely beneficial
to test this method on real data, which unfortunately does not exist at the moment.
With more developed methodology to choose from, it is our hope that data will be-
come available to test this method in the future. This method is a new tool researchers
can use to encourage the implementation of new, patient centered, sequential multiple
treatment assignment trials in precision medicine.
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CHAPTER 5: NONPARAMETRIC INCORPORATION OF PATIENT
PREFERENCES FOR INDIVIDUALIZED TREATMENT RULE
ESTIMATION
5.1 Introduction
To effectively and efficiently treat patients, particular care must be taken when
determining which treatments should be administered and to whom. The population
for any specific disease is vast and diverse and therefore it is not sufficient to apply a
one size fits all approach to health care. Precision medicine is the practice of specifying
healthcare plans, such as treatment allocation, to patients in a way that is best for them
and patients like them. It is a broad term used to describe targeted therapies based a
patient’s genetic information, prognostic variables and past history. The goal is to be
able to determine what patients should be getting what treatments and if they should
be receiving the treatments at all (Jameson and Longo 2015, Sox et al. 2008). In clinical
settings where the patient or doctor is provided with a selection of treatment options,
it may be desirable to include a patient’s preference into decision making. Consider the
treatment of a mental health disorder as a tangible example. We can imagine a scenario
where managing the illness involves understanding how the patient feels about two or
more outcomes, such as efficacy and side effect burden. In this example, as well as in
other therapeutic areas, it is difficult, if not impossible, to quantify how the patient feels
about the two competing outcomes at any instance in time. One solution is to survey a
set of responses from the patient (or clinician) that can be used to mathematically infer
their personal preference evaluation using item response theory (Embretson and Reise
81
2013). This estimation of the patient preferences can then be included when estimating
the optimal treatment rule.
When seeking to estimate a function that maps current patient information to
the treatment space, we formalize it as an individualized treatment rule (ITR). An
optimal ITR is a mathematically dependent treatment plan that mimics how patient’s
are actually treated by their physician. ITRs seek to improve a clinician’s well edu-
cated guess by assigning the treatment that provides the best expected outcome in the
population for patient’s experiencing similar characteristics (Lavori and Dawson 2014).
While there has been a lot of work done for estimating ITRs, there has been limited
progress in developing ITRs that weigh competing outcomes. One way to measure the
trade off between the two competing outcomes is through a linear trade-off. The ques-
tion becomes how do we obtain a weight to define this trade off? Furthermore, how can
we define the relationship between the item response data and the patient preference
if we want a model more flexible than the Rasch model (Rasch 1961)?
In this paper, we propose a nonparametric approach to solving this problem. It is
desirable to use nonparametric estimation because it requires more general assumptions,
which are more realistic in a practical application. During a clinical evaluation, a patient
is instructed to fill out an itemized questionnaire where the responses correspond to one
of two competing outcomes. This serves as parsimonious collection of questions with
binary response options that are used to evaluate how the patient feels about these
outcomes. These outcomes are often associated with the treatment options such that
one treatment elicits a positive effect in one outcome, a negative effect in the other
outcome, and vice versa. Once this item response information is collected, we use it
to estimate the patient’s latent preference. For our purposes, the relationship between
the item responses and the preference information is assumed to be nonparametric.
To find an approximation, we use a piecewise linear splines that are constrained to be
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monotonic (Villalobos and Wahba 1987) and from this create a posterior estimate of
the patient’s preferences given the item responses. This spline model is often referred
to as a broken stick function. A spline is a data smoothing technique that connects
a set of linear functions at connectors called knots. These knots ensure continuity
while the function in between the knots is fit for just that range of values. Splines are
a good nonparametric estimation technique because they allow for flexibility as well
as simplicity of implementation. The parameters within the spline function can then
be estimated subject to a set of necessary constraints using nonlinear programming.
These preferences are normalized and then used to define the patient’s ideal linear trade
off between the two outcomes. To do this, we employ monotonic splines once again
to obtain the relationship between the patient’s satisfaction with the outcomes after
receiving the treatment. This more accurately captures the patient’s feelings on how to
weigh the two outcomes. From this, the linear utility function serves as quantity we wish
to optimize. The optimal treatment rule is that which maximizes the patient’s utility
function. The method is tested in a simulation study which compares the accuracy
of the estimated optimal treatment rule for a sequence of varying samples sizes and
number of response items in the questionnaire.
5.2 Optimal Nonparametric ITRs with Patient Preferences
5.2.1 Framework and Notation
Assume the observed data is defined as {(W i,X i,Ai, Yi, Zi,Bi)}ni=1 which are n
independent and identically distributed observations from (W ,X,A, Y,Z,B). Here,
X ∈ Rm represents patient information preceding the treatment assignment; W ∈{0,1}p represents responses to itemized questionnaire; A ∈ A represents the treatment
assignment; Y ∈ R is the first outcome measured after receiving the assigned treatment;
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Z ∈ R is the second outcome measured after receiving the assigned treatment; B ∈ {0,1}
represents an indicator that that the patient is content with the outcome observed af-
ter receiving treatment. B is only collected during the clinical trial that serves as the
training data set to determine the set of treatment rules. This is to validate how sat-
isfied the patient is with the results of the treatment assignment. In this method, the
responses to the itemized questionnaire, W are used to estimate the latent preference,
E ∈ R.
Under the ITR, pi, a patient with itemized responses W = w and covariates
X = x would be recommended treatment pi(w,x). This is because pi is a map from
the itemized responses and patient covariates to a recommended treatment as. pi ∶
domW ×domX → domA. We define the utility function, U(Y,Z;E), as a composition
of the observed outcomes and the latent preference information, and is intended to serve
as the ultimate outcome of interest in our estimation. We note that the latent preference
information, E, ensures ordering such that, if U(y, z; e) > U(y′, z′; e) patient’s with
E = e prefer outcomes to {Y = y,Z = z} to {Y = y′, Z = z′}. Letting Y ∗(a) and Z ∗ (a)
represent potential outcomes for assigned treatment a, the potential utility function
under a is then U(Y ∗(a), Z∗(a);E) (Rubin 1978). For any pi, the potential utility can
then be defined as VU(pi) = E [∑a∈{−1,1}U {Y ∗(a), Z∗(a);E}1pi(W ,X)=a]. Hence, the
optimal rule is pioptU ∈ arg maxpi VU(pi) for all ITRs pi (Zhao et al. 2012).
To define the nonparametric utility function, we employ monotonic splines (He
and Shi 1998). Let G = Φ(E), where Φ(⋅) is the cumulative distribution function of
a standard normal random variable so that G ∈ [0,1]. Then, define the utility of the
form U(Y,Z;E) = h(G)Y +{1−h(G)}Z, where h is a monotone spline that maps from[0,1] to [0,1]. In this form, the spline will encompass all reasonable utilities. Each of
the splines are constrained to be equal at the interior points, have slopes are positive,
and such that the first linear function has an intercept of 0 and the last linear function
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is constrained such that the summation of the slope and intercept is 1.
If we define:
RZ(w,x) = E{Z∗(1)∣W =w,X = x} −E{Z∗(−1)∣W =w,X = x} ,
RY (w,x) = E{Y ∗(1)∣W =w,X = x} −E{Y ∗(−1)∣W =w,X = x} ,
RU(w,x) = E [U {Y ∗(1), Z∗(1);E} ∣W =w,X = x]
−E [U {Y ∗(−1), Z∗(−1);E} ∣W =w,X = x] ,
then, it can be shown that pioptU (w,x) = sign{RU(w,x)} (Qian and Murphy 2011).
Since h(Φ(E)) is a linear combination of E, from Lemma 3.1 in section 3.2.1, we can
assume the utility function is sufficiently defined as long as the sign of RU(w,x) is
the same as the sign of RY (w,x) or RZ(w,x). This means that the patient would be
content with the optimal policy if if they only care about one of the outcomes.
5.2.2 Estimation
To construct our estimator, piopt, we make three standard causal inference as-
sumptions (Robins et al. 2000, Zhang et al. 2012b): (C1) consistency,(Y,Z) = {Y ∗(A), Z∗(A)}; (C2) positivity, for each a there exists  > 0 such that
P (A = a∣X,W ) ≥ ; (C3) ignorability, [{Y ∗(a), Z∗(a)} ∶ a ∈ {−1,1}] ⊥ A∣X,W . The
consistency assumption implies that the individual’s observed outcome is the potential
outcome associated with the observed exposure; the positivity assumption implies there
is a positive probability of receiving all possible treatments; the ignorability assump-
tion implies that patients receiving all possible treatments have equal distributions of
experiencing the potential outcomes. We further assume (C4) (A,Y,Z) ⊥ E∣X,W ,
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which states that the treatment assignment and responses are independent of a pa-
tient’s preference. This important assumption is reasonable in the single stage scenario
because the treatments are assigned randomly and if outcomes were affected by the
preferences, treatments would be obsolete. Under these stated assumptions, it can
be shown (Schulte et al. 2014) that the optimal individualized treatment can then be
defined in terms of the predefined utility function:
piopt(x,w) =arg max
a∈{−1,1}E[U(Y,Z;E)∣X = x,W =w,A = a]=arg max
a∈{−1,1}E[h(G)Y + {1 − h(G)}Z ∣X = x,W =w,A = a]
=arg max
a∈{−1,1} [E{h(G)∣X = x,W =w}E (Y ∣X = x,W =w,A = a)
+ [1 −E{h(G)∣X = x,W =w}]E (Z ∣X = x,W =w,A = a) ]
=arg max
a∈{−1,1} [µ(x,w)QY (x,w,a) + [1 − µ(x,w)]QZ(x,w, a)],
where QY (x,w, a) = E(Y ∣X = x,W = w,A = a), QZ(x,w, a) = E(Z ∣X = x,W =
w,A = a) and µ(x,w) = E{h(G) ∣X = x,W =w}. Now let Q̂Y,n(x,w, a), Q̂Z,n(x,w, a)
and µ̂n(x,w) be respective estimators of QY (x,w,a), QZ(x,w, a) and µ(x,w). Then,
p̂in(x,w) = arg max
a∈{−1,1} [µ̂n(x,w)Q̂Y,n(x,w, a) + {1 − µ̂n(x,w)} Q̂Z,n(x,w, a)]
This implies that estimation piopt(x,w) can be broken down into three estimators:
Q̂Y,n(x,w, a), Q̂Z,n(x,w, a) and µ̂n(x,w)
To define Q̂Y,n(x,w, a) and Q̂Z,n(x,w, a), we further assume Y,Z ⊥W ∣X. This
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means that the itemized response information contained in W as it relates to the out-
comes is sufficiently captured in the covariates X and need not be included in our
estimator. Then, we construct linear working models as QY (x,w, a;γY ) = x⊺Y,0γY,0 +
ax⊺Y,1γY,1 and QZ(x,w, a;γZ) = x⊺Z,0γZ,0 + ax⊺Z,1γZ,1, where x`,j for ` = Y,Z and j = 0,1
are known feature vectors constructed from x and γY , γZ are unknown parameter
vectors. Note that we assume a linear working model, but this form is note re-
quired and was just assumed for simplicity. Let γ̂Y,n and γ̂Z, n be the maximum
likelihood estimates such that γ̂Y,n = arg minγY E{Y −QY (X,W ,A;γY )}2 and γ̂Z,n =
arg minγZ E{Z −QZ(X,W ,A;γZ)}2. Then, utilizing these estimates, we find that
Q̂Y,n(x,w, a; γ̂Y ) and Q̂Z,n(x,w, a; γ̂Z) are the estimators ofQY (x,w, a) andQZ(x,w, a).
Constructing and estimator µ̂n(x,w) is sufficiently more difficult because E is
latent and therefore unobservable. The first step in defining this estimator is finding an
estimate for Φ(E). To develop a latent preference model, we assume that E ⊥X ∣W .
As we will see, this assumption simplifies the construction of the estimator and is
reasonable if X does not contain any additional information about patient preferences
beyond that contained in W . Since Wj is a binary response variable, we can assume
that, conditional on the unobserved e, Wj are independent Bernoulli random variables.
We define the generating model for W as P (Wj ∣E = e) = exp{fj(e)}1+exp{fj(e)} , where fj is
constrained to be a monotone increasing function for j = 1, . . . , p. To solve this we
employ an EM algorithm. In the estimation step we create starting values for E using
the standard Rasch model from traditional item response theory (Rasch 1961; 1980),
which we discussed at length in Section 3.2.2. We note that in the EM algorithm
these starting values will be replaced with estimates of ên as the algorithm progresses
iteratively.
With these starting values, e0, we start the maximization step by finding f̂j(e0)
using monotone spline smoothing. Let KE be the number of knots such that the knots,
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{t1,e, . . . , tkE ,e} are quantiles of e0. For computational and asymptotic simplicity, we
impose piecewise linear splines and let pij(e0) = {pij,1(e0), pij,2(e0), . . . , pij,KE(e0)}T be
the set of splines of order 2. We then estimate fj by f̂j,n(e0) = pij(e0)T . Define the
linear component as pij,k = aj,k + b∗j,ke0 for k = 1, . . . ,KE. The linear parameters aj,k, bj,k
for a fixed j and all k = 1, . . . ,KE are simultaneously estimated by solving the following
equation using nonlinear programming (Ghalanos and Theussl 2015, Ye 1987):
pij,k(e0) = aj,k + b∗j,ke0 ∀ k ∈ {1, . . . ,KG}
where logit{P (Wj = 1∣E = e)} = pij(e(0))
s.t.
aj,k > 0, bj,k > 0 ∀ k ∈ {1, . . . ,KE}
aj,k + bj,ktk,E = aj,k+1 + bj,k+1tk,E ∀ k ∈ {1, . . . ,KE}.
Because the Wj are independent for j ∈ 1, . . . , p, this process is repeated for all j.
Let βE = {a1,1, b1,1, . . . , a1,KE , b1,KE , . . . , ap,1, bp,1, . . . , ap,KE , bp,KE}. Once we have
estimates β̂E for βE, we can create an estimator of e, ên. Given β̂E and a marginal
distribution for the latent patient preferences, the conditional distribution of E given
W =w is proportional to p(w∣h)ph(h). This can be approximated using a Metropolis
Hastings algorithm. However, because we assume that µ(x,w) does not depend on x,
it is less computationally intensive to apply a method of moments estimator. We let
ên denote the solution to ∑pj=1 b̂j,lexpit (âj,l + b̂j,le) = ∑pj=1 b̂j,lwj ∀ l = 1, . . . ,KE, where
expit(u) = exp(u)/ {1 + exp(u)}. This estimator for e, ên, provides similar estimates
as the Metropolis Hastings algorithm while being significantly less computationally
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burdensome.
Finally, recall that we only collect the contentment information, B, to develop
our rule. We need to incorporate that information into the estimate of h(Ĝ), which
serves as linear trade off weight. To do this, we assume the distribution of B is de-
pendent on the composite outcome, which is a function combination of the outcomes
and the preference information as U(Y,Z; ên) = h(Ĝ)Y + {1 − h(Ĝ)}Z. Hence, we
are interested in is an estimator for h(Ĝ) that optimizes that patients contentment.
We assume that logit{P (B = 1)} = r{U(Y,Z; ên)}, where r is a monotone increasing
function. Let Ĝ = Φ(ên), then, similar to what we have previously done, we fit this
model using monotone spline smoothing except this time we simultaneously fit h(Ĝ)
and r{U(Y,Z; ên)} as piecewise linear splines. LetKG be the number of knots such that
the knots {t1,G, . . . , tKG,G} are quantiles of Ĝ. Under these specifications, we impose
splines pih(Ĝ) and pir{U(Y,Z; ên)} where pih(Ĝ) = {pih,1(Ĝ), pih,2(Ĝ), . . . , pih,KG(Ĝ)}
and pir{U(Y,Z; ên)} = [pir,1{U(Y,Z; ên)}, pir,2{U(Y,Z; ên)}, . . . , pir,KG{U(Y,Z; ên)}] for
h(Ĝ) and r{U(Y,Z; ên)} respectively. Then, we solve the nonlinear function:
89
pir,k{U(Y,Z; ên)} = δ1,k + δ2,kU(Y,Z; ên) ∀ k ∈ {1, . . . ,KG}
where logit{P (B = 1)} = pir{U(Y,Z; ên)}
and U(Y,Z; ên) = h(Ĝ)Y + {1 − h(Ĝ)}Z,
pih,k(Ĝ) = α1,k + α2,kĜ ∀ k ∈ {1, . . . ,KG}
where h(Ĝ) = pih(Ĝ)
s.t.
δ2,k > 0, α2,k > 0 ∀ k ∈ {1, . . . ,KG}
α1,1 = 0
α1,KG + α2,KG = 1
α1,k + α2,ktk,G = α1,k+1 + α2,k+1tk,G ∀ k ∈ {1, . . . ,KG}
δ1,k + δ2,ktk,G = δ1,k+1 + δ2,k+1tk,G ∀ k ∈ {1, . . . ,KG}
Then, the estimator of µ(x,w) is µ̂n(x,w) = ĥ(Ĝ).
5.3 Simulation Study
The results of the simulation study are included for 3 knots, which has been
shown to be sufficient by He and Shi (1998). For completeness, similar results for 5
knots are included in the Appendix B.1. We chose 3 knots because additional knots
do not provide enough additional information to justify a more complex model with a
burdensome computation.
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5.3.1 Setup and Assumptions
The simulation study considered the following class of models. The patient prefer-
ences are assumed to be i.i.d. from a standard normal distribution such that E ∼ N(0,1).
We designate h(G) to be a piecewise linear spline that is data dependent. With
U(Y,Z;E) = h(G)Y + {1 − h(G)}Z, the contentment observation, B, is assumed to
be i.i.d. from a Bernoulli distribution such that B ∼ Bernoulli{expit(r{U(Y,Z; e)})},
where r{U(Y,Z; e) is a piecewise linear spline. The itemized responses are assumed to
be i.i.d. from a Bernoulli distribution such that Wj ∼ Bernoulli{expit(f(E))}, where
f(E) is a piecewise linear spline. The treatment, covariates, and outcome data were
drawn i.i.d. so that: A ∼ Unif{−1,1}, X ∼ N5(µ, I5), Y = X⊺γY,0 + AX⊺γY,1 + 
and Z = X⊺γZ,0 + AX⊺γZ,1 + δ where , δ ∼ N(0,1), γ00 = (2.5, .2, .25,−.7,−2.5,2.4),
γ01 = (1.7,−2.3,4.5,6,−7.3,−1.6), γ10 = t + q∗γ00 and γ11 = t + q∗γ01. We set q = −2 and
t = 3 so that the outcomes favor different treatments about 80% of the time.
5.3.2 Simulation Results
The simulations were each repeated s = 500 times for all combinations of n =
25,50,100,150, 200 and p = 5,10,20,30,40. To check the accuracy of this method,
it is beneficial to dissect the estimator and check the accuracy of each component.
Since Q̂Z,n(x,w, a) and Q̂Z,n(x,w, a) have been simplified to linear regression, we
are satisfied with the asymptotic properties of γ̂Z,n, γ̂Y,n (Craven and Islam 2011). To
measure the accuracy of µ̂n(x,w), we look at the mean squared error betweenG = Φ(E)
and Ĝ = Φ(Ê) and between µ̂n(x,w) and µ(x,w). The results are found in Figure
5.1. In both cases, the mean squared error decreases as n and p increases. Figure 5.2
contains the true and estimated piecewise linear spline for µn(x,w) = h(G). While, for
the most part, the estimated spline is close to the true function, there is deviation in
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the tails of the distribution.
Figure 5.1: Mean squared error: G = Φ(E) and µ̂n(x,w)
a : MSE of Ĝ = Φ(Ê) b : MSE of µ̂n(x,w)
Figure 5.2: Estimated and true piecewise linear splines for µn(x,w) = h(G).
We obtained the mean squared error between the estimated value function and
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the true value functions for the marginal outcomes. The results are shown in Figure
5.3 which shows the average difference between V̂Y (p̂in) = E [maxa Q̂Y (X,W , a)] and
VY (pioptn ) and between V̂Z(p̂in) = E [maxa Q̂Z(X,W , a)] and VZ(pioptn ) on the right. As
expected, the quality of the approximation improves as n increases but is insensitive
to changes in p. This is what we would expect because neither of the outcomes are
affected by the itemized questionnaire responses.
Figure 5.3: Mean squared error: V̂Y (p̂in) and V̂Z(p̂in)
a : MSE of V̂Y (p̂in) b : MSE of V̂Z(p̂in)
Figure 5.4 contains the mean squared error between the estimated value func-
tion V̂U(p̂in) = E [maxa Q̂U(X,W , a)] and the true value function of the optimal rule,
VU(piopt) on the left and the percent of times the optimal treatment was mislabeled
when compared to the true optimal treatment rule on the right. Except for when
n = 25 and p = 5, we see that proposed estimation method performs better as sample
size and items diverge. When n = 25 there is no discernible trend as p increases. There
is a similar pattern when we fix p = 5 and look as n increases. These values may be too
small to have desirable estimation properties.
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Figure 5.4: Mean squared error: V̂U (p̂in) and piopt
a : MSE of V̂U(p̂in) b : Average disagreement between p̂in and piopt
5.4 Discussion
We have presented a nonparametric approach to estimating ITRs. The nonpara-
metric assumption is employed in two separate steps of the estimation procedure to
ensure reasonable flexibility within the estimator. In this instance, the benefit of this
nonparametric model is increased accuracy when estimating the patient’s conditional
latent preference. While the logical form of the utility function remains a linear func-
tion of the outcomes, employing a nonparametric model to determine the "weights"
allows a more accurate trade-off in that it accounts for the patient’s satisfaction of the
resulting outcomes after receiving the treatment. The method also maintains desirable
asymptotic properties since it becomes more accurate as we increase the sample size
and the number of items on the questionnaire.
While this method is rich in its development and represents a clear advancement in
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the field of precision medicine, there are many potential extensions and enhancements.
A reasonable next step is to expand this to 3 or more outcomes. This will impact
the construction of the utility function, as well as the estimation of the latent trait.
We also anticipate the added complexity of the model will make the algorithm more
computationally intensive. This method could also be extended to consider a non linear
spline component or another form of nonparametric estimation. Finally, it would be
interesting to see the impact of loosening some restrictions on independence as it may
be pragmatic to incorporate patient covariate information, and not just the itemized
response information, into the spline estimation. Although this work provides a path in
a promising direction, it is not without limitations. To ensure computational efficiency,
only a piecewise linear spline was employed, and this broken stick model may not
be the best representation of the underlying trends. The EM algorithm employed to
estimated the conditional mean of the latent preference information is contingent on
the parametrically estimated starting values for the preference information. There may
be a better way to develop starting values that will lead to robust parameter estimates,
such as jittering the starting values, but it has not been explored for our purposes. It
also may be interesting to develop another way to incorporate the patient’s satisfaction
with the outcomes after receiving treatment aside from what we have already described.
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CHAPTER 6: DISCUSSION
The goal of this research was to develop a set of estimation strategies that integrate
patient preferences when balancing two competing outcomes. There is a logical fluidity
and progression throughout the work presented here. The first setting is the single
stage estimation of individualized treatment rules. Upon evaluation of this method
and its extension to the multiple stage setting, it was clearly necessary to calibrate how
satisfied the patient is with the results of their treatment assignment and incorporate
that in the later stage estimation model. While the preference information provides a
measure of how much the patient conceptually prefers one outcome over the other, the
patient’s contentment measures if the treatment resulted in desirable outcomes. Moving
forward with the nonparametric approach, this contentment measure was included for
the same reasons, even though the nonparametric model is only currently developed
for the single stage setting. In application, it may be valuable to incorporate the
contentment measure in the parametric model as well.
While there are many nonparametric estimation strategies, the one chosen for
this work was a monotone spline. Splines were chosen because of their flexibility in the
number of knots assigned and the ease of interpretation and implementation. There is
great potential in comparing multiple nonparametric estimation procedures to deter-
mine which are the most computationally efficient as well as the most precise. Linear
splines were chosen for the model presented because of the asymptotic guarantees de-
fined and verified in the parametric model. There is more theoretical research to be
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done to verify these asymptotic properties for quadratic or cubic splines. The non-
parametric model was also only defined here for single stage estimation. It is ideal
to develop an extension that performs this estimation for sequential decision making.
It is theorized that a similar evolving preference model with Q-learning would be the
best implementation, but further research is required to delve into the semantics of
the estimation model. The form of the contentment measure only allows for a binary
response of "content" or "not content". It may be beneficial to allow contentment to be
measured on an ordinal scale or as an aggregate measure on a series of items, perhaps
as analyzed through item response theory.
There is also vast interest in extending this work to include more than two out-
comes, which requires a latent trait model for polytomous data. These can be in-
tegrated using Samejima’s graded response model and the generalized partial credit
model. Ideally, both methods would be compared to determine which performs the
best. Samejima’s graded response model is an extension of traditional item response
theory but instead of assuming dichotomous responses, it assumes ordered polytomous
categories (Samejima 1972). The graded response data consists of a set of items where
the score of each item is an ordinal number ranging from 0 to m. The model measures
the cumulative probability that person i responds to category k or lower to the jth
item. Conversely, the generalized partial credit model hinges on the assumption that
the probability of a subject selecting the kth category over all other categories is con-
trolled by the traditional dichotomous latent trait model (Muraki 1992). Both of these
models have presence in current literature, so a more extensive investigation would be
needed to determine which provides more desirable properties. While these are two
clear choices to develop this model for 3 or more outcomes, it is quite possible that
there may be a better model all together.
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One of the fundamental assumptions of this work is that estimation of the prefer-
ence information is independent of the covariates and the estimation of the conditional
marginal outcomes is independent of the itemized response data. This requires both
the covariates and the itemized response data to be rich enough to contain sufficient
information without the presence of the other. This requires diligent and thorough col-
lection of the data, which may not always be possible. While it is reasonable to make
these assumptions for this research, relaxing them may lead to a more generalizable
model.
Finally, because of the potential practical significance of this work, it is of utmost
importance to design, fund and implement trials that produce the well defined data
required for this work. The ideal data structure only requires a small amount of addi-
tional information to collect and its collection is relatively simple and inexpensive. This
will allow for not only refinement of the methodology, but more importantly provide
operationalized treatment decisions that will only further advance precision medicine.
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APPENDIX A: DETAILS FOR CHAPTER 3
A.1 Consistency Proof Details
We will first show that β̂n = (β̂n,0,1, β̂n,1,1, . . . , β̂n,0,p, β̂n,1,p) is consistent for β =(β0,1, β1,1, . . . , β0,p, β1,p). Arcones (2006) and Fu, Li, and Zhao (1993) provide consis-
tency results for the Rasch model that do not directly address the particulars of this
model and do not allow for a large increase in sample size. The work presented here
is intended to be a more generalized result. We need the following lemma and remark
before giving the consistency proof in Theorem 1 below.
Lemma A.1.1. For each j ∶ 1 ≤ j ≤ p, let Xn1,j, . . . ,Xnnj be iid∼ Bernoulli(pinj ). Let
p̂inj = n−1 n∑
i=1Xnij. Then,
max
1≤j≤p ∣p̂inj − pinj ∣→p 0, as n→∞, (6.1)
provided p = o(en).
Proof. Let F̂ nj (t) = n−1 n∑
i=1 1{Xnij ≤ t} ∀ t ∈ R,1 ≤ j ≤ p. Since p̂inj = 1 − F̂ nj (12), the result
follows from Theorem 15.12 of Kosorok (2008). ∎
Remark 1: Provided lim inf
n→∞ min1≤j≤ppinj > 0, (6.1) can be strengthened to
max
1≤j≤p ∣ p̂injpinj − 1∣→p 0, as n→∞,
provided p = o(en).
Theorem A.1.2. Assume
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(i) we have 3 ≤ p = o(en) items with β0 satisfying that ∃ 0 < δ < 12 so that −δ−1 ≤
β0,j,0 ≤ δ−1 and δ ≤ β1,j,0 ≤ δ−1 ∀ 1 ≤ j ≤ p and all n ≥ 1;
(ii) we observe n iid individuals with p items, {Nij,1 ≤ j ≤ p}, where, conditional on
latent trait e ∼ N(0,1), P (Nij ∣e) = Pj(β0, e), 1 ≤ j ≤ p.
Then ∃ an estimator of β0, β̂n, such that
max
1≤j≤p(∣β̂0,j,n − β0,j,0∣ ∨ ∣β̂1,j,n − β1,j,0∣)→p 0, as n→∞.
Proof. For each n, divide the p items into m groups Kl,1 ≤ l ≤ m, where the groups
contain between three and 3 <M <∞ item indices such that Kl ⊂ {1, . . . , p}, there are
no duplicated indices across the m groups, and that
m⋃
l=1Ke = {1, . . . , p} and m∑l=1 kl = p,
where kl = #Kl,1 ≤ l ≤ m (i.e., each index is represented one and only one time in the
m sets). If p is fixed, then M can be set equal to p and m = 1. MLE estimation will
be done for β0 in subgroups defined by Kl. More specifically, for 1 ≤ l ≤ m, we will
estimate {β0,j, j ∈Kl} though maximizing
(βj, j ∈Kl)↦ n∑
i=1 log(
ˆ
R
exp{∑
j∈KlNij(β0,j + β1,je) − log (1 + eβ0,j+β1,je)}Φ(e)de) , (6.2)
where βj = (β0,j, β1,j) and φ is the standard normal density.
Let Ul = {0,1}Kl and for each u ∈ Ul, where u = (uj, j ∈ Kl), define Nu = #{i ∶
Nij = uj, j ∈Kl}, where the j′s in Kl are in ascending order (for easier tracking).
For each u ∈ Ul, also define
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Puβ) = ˆ
R
∏
j∈Kl ( e
β0,j+β1,je
1 + eβ0,j+β1,je)uj ( 11 + eβ0,j+β1,je)1−uj Φ(e)de.
Then, (6.2) can be rewritten as
(βj, j ∈Kl)↦ ∑
u∈UlNu logPu(β).
Take β̂n = (β̂j,n,1 ≤ j ≤ p) to be the maximizers of
(βj, j ∈Kl)↦ ∑
u∈Ul
Nu
n
logPu(β), ∀ 1 ≤ l ≤m,
and note that by the consequences of being maximizers,
∑
u∈Ul
Nu
n
logPu(β0) ≤ ∑
u∈Ul
Nu
n
logPu(β̂n) ≤ 0, ∀1 ≤ l ≤m. (6.3)
Note that the requirements on β0 ensure that ∃ 0 <  < 12 such that  ≤ Pu(β0) ≤
1 −  ∀ u ∈ Ul, 1 ≤ l ≤m, and all n ≥ 1. Thus both
∑
u∈Ul logPu(β0) = Op(1) and ∑u∈Ul logPu(β̂n) = Op(1), (6.4)
where the Op(1) is universally bounded for all 1 ≤ l ≤ m. This follows from
the trapping of ∑
u∈Ul logPu(β̂n) in (6.3). Lemma 3.4 and Remark 1 now imply that
Nu/n = Pu(β0)(1 + op(1)), where the op(1) is uniform over all u ∈ Ul,1 ≤ l ≤ m. This
combined with (6.3) and (6.4) implies that op(1) ≤ ∑
u∈UlPu(β0) log(Pu(β̂n)Pu(β0)) ≤ 0, where
op(1) is uniform over all u ∈ Ul,1 ≤ l ≤m. This now implies that
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op(1) = min
1≤l≤m ∑u∈UlPu(β0) log(Pu(β̂n)Pu(β0))
≤ max
1≤l≤m ∑u∈UlPu(β0) log(Pu(β̂n)Pu(β0))≤ 0,
which implies that
max
1≤j≤p(∣β̂0,j,n − β0,j,0∣ ∨ ∣β̂1,j,n − β1,j,0∣)→p 0, as n →∞,
by the properties of the Kullback-Leibler divergence and the identifiability of the con-
stituent models. ∎
From standard consistency results for linear regression, we know that Ê(Y ∣X =
x,A = a) is consistent for E(Y ∣X = x,A = a) and Ê(Z ∣X = x,A = a) is consistent for
E(Z ∣X = x,A = a). Now, let
Q̂n(x,w, a) = Ê(Φ(e)∣W = w))Ê(Y ∣X = x,A = a)+
(1 − Ê(Φ(e)∣W = w)))Ê(Z ∣X = x,A = a)
and
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Q0(x,w, a) = E(Φ(e)∣W = w)E(Y ∣X = x,A = a)+
(1 −E(Φ(e)∣W = w)E(Z ∣X = x,A = a).
Then p̂ioptn (x,w) = arg maxa Q̂n(x,w, a) and piopt0 (x,w) = arg maxaQ0(x,w, a).
Note that p̂ioptn (x,w) is asymptotically equivalent to piopt0 (x,w) if the expectation
for the value function for p̂ioptn (x,w) is asymptotically equivalent to the expectation of
the value function for piopt0 (x,w) as n, p→∞. Hence, it is sufficient to show
EX,W (Q0(X,W, p̂ioptn (X,W ))) −EX,W (Q0(X,W,piopt0 (X,W )))→p 0 as n →∞, (6.5)
provided we require p→∞ as n→∞.
Lemma A.1.3. If max
a
(EX,W ∣Q̂n(X,W,a) −Q0(X,W,a)∣)→p 0 then (6.5) holds.
Proof. Let
EX,W (∆n(X,W )) ≡ EX,W (max
a
∣Q̂n(X,W,a) −Q0(X,W,a)∣)
≤ EX,W (∑
a
∣Q̂n(X,W,a) −Q0(X,W,a)∣)
≤ #(A)max
a
(EX,W ∣Q̂n(X,W,a) −Q0(X,W,a)∣)
where #(A) is the number of treatment choices which is assumed to be finite. Thus,
EX,W (∆n(X,W ))→ 0 from the assertion in Lemma 2.
By definition of piopt0 and p̂i
opt
n , for any X,W , and since Q̂n(X,W,piopt0 (X,W )) ≤
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Q̂n(X,W, p̂ioptn (X,W )), we have:
0 ≤ Q0(X,W,piopt0 (X,W )) −Q0(X,W, p̂ioptn (X,W ))= Q0(X,W,piopt0 (X,W )) − Q̂n(X,W,piopt0 (X,W )) + Q̂n(X,W,piopt0 (X,W ))− Q̂n(X,W, p̂ioptn (X,W )) + Q̂n(X,W, p̂ioptn (X,W )) −Q0(X,W, p̂ioptn (X,W ))
≤ 2∆n(X,W ).
Hence,
EX,W ∣Q0(X,W, p̂ioptn (X,W ))−Q0(X,W,piopt0 (X,W ))∣ ≤ 2E(∆n(X,W ))→p 0, as n →∞,
and thus (6.5), and therefore Lemma 2, holds. ∎
Lemma A.1.4. Assume the following:
(i) sup
w
∣Ê(Φ(e)∣W = w) −E(Φ(e)∣W = w)∣→p 0, as n→∞;
(ii) (a) max
a
EX ∣Ê(Y ∣X,A = a) −E(Y ∣X,A = a)∣→p 0, as n→∞;
(b) max
a
EX ∣Ê(Z ∣X,A = a) −E(Z ∣X,A = a)∣→p 0, as n→∞.
Then maxaEX,W ∣Q̂n(X,W,a) −Q0(X,W,a)∣→p 0, as n→∞.
Proof. This follows directly from (i) and (ii) combined with the definitions of Q̂n and
Q0. ∎
The following theorem gives us the desired consistency of both Ê(Φ(e)∣W = w)
and E˜(Φ(e)):
Theorem A.1.5. Assume:
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(i) p→∞ as n→∞;
(ii) ∃ 0 < δ < 12 such that ∣β0,j ∣ ≤ δ−1 and δ ≤ βi,j ≤ δ−1 for all 1 ≤ j ≤ p and all p ≥ 1;
(iii) max
1≤j≤p(∣β̂n,0,j − β0,j ∣ ∨ ∣β̂n,1,j − β1,j ∣)→p 0, as n→∞;
Then:
(a) max
w
∣Ê(Φ(e)∣W = w) −E(Φ(e)∣W = w)∣→p 0,
(b) max
w
∣E(Φ(e)∣W = w) −Φ(e˜p(β0,w))∣→p 0,
(c) max
w
∣Φ(e˜p(β̂n,w)) −Φ(e˜p(β0,w))∣→p 0,
as n→∞.
Proof. The assumptions imply that ∣β̂0,j,n∣ ≤ 2/δ and δ/2 ≤ β̂n,1,j ≤ 2/δ with probability
approaching 1 as n→∞. To achieve convergence in probability, we can assume it holds
hereafter for all n without loss of generality.
Let qp(e, β̂n,w) = p∑
j=1 β̂1,j,nwje − p∑j=1 log(1 + eβ̂0,j,n+β̂1,j,ne) and note that
Ê(Φ(e)∣W = w) =
ˆ
R
Φ(e)eqp(e,β̂n,w)Φ(e)de
ˆ
R
eqp(e,β̂n,w)Φ(e)de .
Note also that
∂
∂e
qp(e, β̂n,w) = p∑
j=1 β̂1,j,n(wj − Pj(β̂n, e))
and ( ∂
∂e
)2qp(e, β̂n,w) = − p∑
j=1 β̂21,j,nPj(β̂n, e)(1 − Pj(β̂n, e)) < 0.
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Hence, e↦ qp(e, β̂n,w) has a unique maximum at e˜p(β̂n,w). Now define
q˜p(e, β̂n, b) = p∑
j=1 β̂1,j,n
⎛⎜⎜⎜⎜⎜⎝
eb −
p∑
j=1 log(1 + eβ̂0,j,n+β̂1,j,ne)
p∑
j=1 β̂1,j,n
⎞⎟⎟⎟⎟⎟⎠
,
and let e′p(β, b) be the unique value of e solving
p∑
j=1β1,jb = p∑j=1β1,jPj(β, e),
for any b ∈ [0,1]. Then
sup
w
∣Ê (Φ(e)∣W = w) −Φ (e˜p(β̂n,w)) ∣ ≤
sup
b∈[0,1]
RRRRRRRRRRRRRRRRRR
ˆ
R
Φ(h)eq˜p(e,β̂n,b)−q˜p(e′p(β̂n,b),β̂n,b)φ(e)de
ˆ
R
eq˜p(e,β̂n,b)−q˜p(e′p(β̂n,b),β̂n,b)φ(e)de −Φ(e′p(β̂n, b))
RRRRRRRRRRRRRRRRRR
≡ sup
b∈[0,1] Ân(b).
Therefore, once we show that sup
b∈[0,1] Ân(b)→ 0 and (c), then we are able to conclude
(a).
Fix b ∈ (0,1). Note that q˜p(e, β̂n, b) − q˜p(e′p(β̂n, b), β̂n, b) ≤ 0 ∀ e with equality
only if e ≡ e′p(β̂n, b). From previous derivations,
− log ∣( b1−b)∣ − 2/δ
δ/2 ≤ e′p(β̂n, b) ≤ ∣log ( b1−b)∣ + 2/δδ/2 ; (6.6)
and, moreover,
Pj(β̂n, e)(1 − Pj(β̂n, e)) ≥ e−2/δ−(2/δ)∣e∣
1 + e−2/δ−(2/δ)∣e∣ ( 11 + e2/δ+(2/δ)∣e∣) ≡ e(δ, e), ∀ e ∈ R.
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Thus:
0 < e(δ, h)δ
2
≤
p∑
j=1 β̂21,j,nPj(β̂n, e)(1 − Pj(β̂n, e)
p∑
j=1 β̂1,j,n
∀ e ∈ R.
Hence, for any e ∈ R,
q˜p(e, β˜n, b) − q˜p(e′p(β˜n, b), β˜n, b)∑pj=1 β˜1,j ≤ −δe(δ, e˜)4 (e − e′p(β˜n, b))2,
where e˜ is on the line segment between e and e′p(β˜n, b). By (6.6), e′p(β˜n, b) is uniformly
bounded for any fixed b ∈ (0,1) and for all p ≥ 1. Hence for any
e ≠ e′p(β˜n, b), p [q˜′p(e, β˜n, b) − q˜′p(e′p(β˜n, b), β˜n, b)]→p ∞. Thus, ∀ b ∈ (0,1), Ân(b)→p 0.
Letting B̂n(b) =
ˆ
R
Φ(e)eq˜p(e,β˜n,b)Φ(e)deˆ
R
eq˜p(e,β˜n,b)Φ(e)de , we have that
∂
∂b
B̂n(b) =
ˆ
R
Φ(e)(e − t′p(β̂n, b))eq˜p(e,β˜n,b)Φ(e)deˆ
R
eq˜p(e,β˜n,b)Φ(e)de , (6.7)
where t′p(β, b) =
ˆ
R
e∗eq˜p(e,β,b)Φ(e)deˆ
R
eq˜p(e,β,b)Φ(e)de .
Hence (6.7) is the covariance between two monotonically increasing functions of
e, which implies (6.7) > 0. Hence B̂n(b) is monotonically increasing in b. Similarly it
is also easy to show that Φ(e′p(β̂n, b)) is monotonically increasing in b.
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By definition of e′p(β̂n, b), we have that
∂
∂e
e′p(β̂n, b) =
⎛⎜⎜⎜⎜⎜⎝
p∑
j=1 β̂2n,1,jPj(β̂n, e)(1 − Pj(β̂n, e))
p∑
j−1 β̂n,1,j
⎞⎟⎟⎟⎟⎟⎠
−1
,
and thus for any 0 < ρ < 12 , both
lim sup
n→∞ supb∈[ρ,1−ρ]
∂
∂b
e′p(β̂n, b) <∞
and
lim sup
n→∞ supb∈[ρ,1−ρ]
∂
∂b
e′p(β0, b) <∞,
where both ∂∂be
′
p(β˜n, b) and ∂∂be′p(β0, b) are also > 0 for all b ∈ [0,1] and all p ≥ 1.
Therefore, ∀ ρ > 0, ∃ 0 < b1 < . . . < bk < 1 such that
0 ≤ Φ(e′p(β0, bj+1)) −Φ(e′p(β0, bj)) ≤ ρ (6.8)
∀ 0 ≤ j ≤ k, where b0 = 0 and bk+1 = 1. Previous arguments show that Φ(e′p(β̂n, b)) −
Φ(e′p(β0, b)) →p 0, as n → ∞ ∀ b ∈ (0,1). This, combined with (6.8) and the mono-
tonicity of b↦ Φ(e′p(β˜n, b)), yields that
sup
b∈[0,1] ∣Φ(e′p(β̂n, b)) −Φ(e′p(β0, b))∣→p 0, as n →∞. (6.9)
This result, combined with the fact that B̂n(b) in monotone in b and contained in[0,1], as well as the fact that Ân(b) →p 0 ∀ b ∈ (0,1), implies that supb∈[0,1] Ân(b) →p,
as n→∞.
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This now implies that
max
w
∣Ê(Φ(e)∣W = w) −Φ(e˜p(β̂n,w))∣→p 0. (6.10)
The previously presented smoothness results now imply that for all {an},{bn} ∈ [0,1]
such that ∣an − bn∣→p 0, Φ(e′p(β̂n, an)) −Φ(e′p(β0, bn))→p 0, since (6.9) implies
max
w
RRRRRRRRRRRRRRRRRRRRR
Φ
⎛⎜⎜⎜⎜⎜⎝
e˜′p
⎛⎜⎜⎜⎜⎜⎝
β̂n,
p∑
j=1 β̂1,j,nwj
p∑
j=1 β̂1,j,n
⎞⎟⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎟⎠
−Φ
⎛⎜⎜⎜⎜⎜⎝
e˜′p
⎛⎜⎜⎜⎜⎜⎝
β0,
p∑
j=1 β̂1,j,nwj
p∑
j=1 β̂1,j,n
⎞⎟⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎟⎠
RRRRRRRRRRRRRRRRRRRRR
→p 0. (6.11)
Note that previous arguments yield
max
w
RRRRRRRRRRRRRRRRRRRRR
p∑
j=1 β̂1,j,nwj
p∑
j=1 β̂1,j,n
−
p∑
j=1β1,j,0wj
p∑
j=1β1,j,0
RRRRRRRRRRRRRRRRRRRRR
→p 0.
Now suppose that
max
w
RRRRRRRRRRRRRRRRRRRRR
Φ
⎛⎜⎜⎜⎜⎜⎝
e˜′p
⎛⎜⎜⎜⎜⎜⎝
β0,
p∑
j=1 β̂1,j,nwj
p∑
j=1 β̂1,j,n
⎞⎟⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎟⎠
−Φ
⎛⎜⎜⎜⎜⎜⎝
e˜′p
⎛⎜⎜⎜⎜⎜⎝
β0,
p∑
j=1β1,j,0wj
p∑
j=1β1,j,0
⎞⎟⎟⎟⎟⎟⎠
⎞⎟⎟⎟⎟⎟⎠
RRRRRRRRRRRRRRRRRRRRR
/→p 0. (6.12)
Then ∃ a sequence {wn} such that
p∑
j=1 β̂1,j,nwnj
p∑
j=1 β̂1,j,n
−
p∑
j=1β1,j,0wnj
p∑
j=1β1,j,0
/→p 0.
Since this contradicts (6.7), (6.12) must not be true. Hence, by (6.11), max
w
∣Φ(e˜p(β̂n,w))−
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Φ(e˜p(β0,w))∣→p 0, and (c) follows.
Combining these results with (6.10), we now have that maxw ∣Ê(Φ(e)∣W = w) −
Φ(e˜p(β0,w))∣ →p 0 as n → ∞. All of the above arguments hold true if β̂n is replaced
with β0. This then implies maxw ∣E(Φ(e)∣W = w)−Φ(e˜p(β0,w))∣→p 0 as n→∞. Thus,
(b) and (a) follow, hence the proof is complete. ∎
Remark 2: Theorem 2 demonstrates that we can approximate Ê(Φ(e)∣W = w)
with Φ(e˜p(β̂+n ,w)) uniformly on w where β̂+n = (β˜0n, (β̂1n)+) since, clearly,
max
1≤j≤p ∣β̂+1,j,n − β̂1,j,n∣→p 0.
A.2 Comparison of µ̂MHE,n (x,w) and µ̂MoME,n (x,w) Details
We first compared the absolute difference between the Metropolis Hastings and
method of moments estimator, ∣µ̂MHE,n (x,w) − µ̂MoME,n (x,w)∣. The results are found in
Figure 6.1. They show that regardless of n and p, the absolute difference is the greatest
for extreme values of W (closest to 0 and 1) and is much smaller in between. Across
n, the absolute difference between the two methods decreases as p increases.
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Figure 6.1: Absolute difference: µ̂MHE,n (x,w) and µ̂MoME,n (x,w)
Figure 6.2 contains a heatmap of the average absolute difference on the left
and a heatmap of the average maximum absolute difference between µ̂MHE,n (x,w) and
µ̂MoME,n (x,w) on the right. In both plots we see that as n and p increase, the absolute
difference decreases. Collectively, these simulations provide further evidence that the
methods of moments estimator performs as well as the Metropolis Hastings estimator.
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Figure 6.2: Averaged absolute and mean difference: µ̂MHE,n (x,w) and µ̂MoME,n (x,w)
a : Average Absoute Difference b : Maximum Absolute Difference
A.3 Case Study Details
PANSS was the primary assessment instrument the investigators used to assess
psychopathology. The patient is rated from 1 to 7 on 30 different schizophrenic symp-
toms based on a face to face interview. Values range from 30-154, where larger values
imply more severe schizophrenia symptoms. The difference in the PANSS score is the
PANSS score at the discontinuation of phase 1 minus that PANSS score at baseline.
For the sake of the proposed method, the outcome variable is this difference times -
1. If the PANSS score decreases between baseline and discontinuation of phase 1 the
difference will be a positive number and if it increases the difference will be negative.
Hence, larger values are associated with a more favorable outcome.
The second outcome is an aggregate of indicators of side effects and adverse events,
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recorded from multiple sources including systematic inquiry adverse events, serious ad-
verse events, parameters associated with metabolic syndrome, and assessment scales
for tardive dyskinesia and akathisia. Each adverse event or side effect was assigned a
particular weight based on presence and severity. Adverse events were collected via a
systematic inquiry where the patient was able to report adverse events such as constipa-
tion, dry mouth and hypersomnia at the discontinuation of phase 1. Although we chose
to use the information from the last visit, another strategy that could be used, which is
consistent with adverse event reporting standards for clinical trials would be to weight
the scoring based on the most severe reporting of the symptom during the phase. Using
the patient’s indication of the severity of the adverse event, each is weighted as either
1/3 for mild, 2/3 for moderate, or 1 for severe. Serious adverse events were collected via
a spontaneous inquiry (or whenever they arose). The serious adverse event is recorded
if the event occurred within phase 1 or within 30 days of ending phase 1. The most seri-
ous event, death, was removed from this analysis because it would have been weighted
so heavily as to skew the outcome. Serious adverse events include hospitalizations and
even though hospitalizations for psychosis indicate a lack of efficacy, we chose to in-
clude all hospitalizations. An additional option would be to remove hospitalizations for
psychosis as a serious adverse event. All serious adverse events were given a weight of
1, unless they resulted in discontinuation of the medication (hence discontinuing phase
1) then the event was weighted as a 2. Measures of metabolic effects were designated
as adverse events if they exhibited a significant negative change from baseline. (It was
only marked as an adverse event if the patient was not already exhibiting the negative
effect at baseline). For this analysis, the last available measure was included. They will
each be weighted as follows: a pulse rate above 100 was weighted as 1; a waist-hip ratio
between 0.81 and 0.85 was weighted 1/2 while greater than 0.85 received a weight of 1;
a blood glucose level between 100 mg/dL and 125 mg/dL was weighted 1/2 and greater
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than 125 mg/dL was weighted 1; total cholesterol between 200 mg/dL and 239 mg/dL
was weighted 1/2 and greater than 239 mg/dL is weighted 1; HDL cholesterol less than
40 mg/dL was weighted as 1; triglycerides between 150 mg/dL and 199 mg/dL were
weighted 1/3, 200 mg/dL to 499 mg/dL was weighted 2/3 and 500 mg/dL or higher was
weighted 1; patients who experienced a weight gain of 7% or higher were weighted as 1.
If a patient meets the Schooler-Kane criteria for tardive dyskinesia, they were weighted
as 1. If akathisia is present it is listed as mild, moderate, marked, or severe and was
weighted as 1/4, 1/2, 3/4, or 1, respectively. These measurement weights were then
summed up for each patient. Developing the second outcome in this manner makes
larger values less desirable because larger values imply more adverse events. Since the
goal is to reverse this so that larger values are less desirable, the outcome is defined as
Z = ∣Z∗ −max(Z∗)∣. We note that other adverse events were reported by spontaneous
report and were not included in the aggregate side effect calculation because the known
medical concerns for these FDA-approved medications were reasonably covered by the
systematic inquiry AEs, SAEs, parameters associated with metabolic syndrome, and
the assessments for movement disorders
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APPENDIX B: DETAILS FOR CHAPTER 5
B.1 Simulation Results for 5 Knots
Below we find the simulations results plots when we include 5 knots in the mono-
tone spline function. We see that the more complex model does not provide substan-
tially more accurate estimates compared to the models with 3 knots.
Figure 6.3: Mean squared error: G = Φ(E) and µ̂n(x,w)
a : MSE of Ĝ = Φ(Ê) b : MSE of µ̂n(x,w)
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Figure 6.4: Mean squared error: V̂Y (p̂in) and V̂Z(p̂in)
a : MSE of V̂Y (p̂in) b : MSE of V̂Z(p̂in)
Figure 6.5: Mean squared error: V̂U (p̂in) and the average percent difference: piopt
a : MSE of V̂U(p̂in) b : Average disagreement between p̂in and piopt
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